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Chapter 1: Introduction 
1.1 HIV-1 Epidemiology 
 Human immunodeficiency virus (HIV) was first discovered in 1983 as the causative agent of 
Acquired Immune Deficiency Syndrome (AIDS) [1-8]. Significant advances in treatment options have 
been made, resulting in a 24% reduction in AIDS-related deaths since 2005. However HIV/AIDS remains 
a global epidemic  as approximately 34 million people worldwide are living with HIV, with 2.5 million 
infected individuals as of the end of 2011[9].  
Table 1.1 Global summary of the AIDS epidemic as of 2011. Biannually, the World Health Organization, 
the UNAIDS and Unicef provide a detailed epidemiological report on the global AIDS epidemic [9]. 
 
 
1.2 HIV life cycle 
 HIV-1 and HIV-2 are lentiviruses belonging to the Retroviridae family associated with a long 
incubation period which causes immune deficiencies of the hematopoietic system.  The HIV viral life 
cycle begins with attachment of viral particles to host immune cells (Figure 1.1). The primary cell target 
is T4-lymphocytes which express the CD4 receptor on its cell surface. The interaction between the viral 
envelope glycoproteins, gp120 and gp41; with CD4 and its co-receptors, CxCR4 and CCR5 facilitate 
binding and entry into host cells. 
  
 
 
Figure 1.1. The HIV life cycle. This figure was adapted from an original illustration by Dominic Doyle at 
Vanderbilt University. 
 
  Following membrane fusion, the viral capsid containing two copies of the viral RNA genome, 
reverse transcriptase, and integrase; is released into the cell. After uncoating of the capsid, reverse 
transcriptase reverse transcribes the RNA to DNA and subsequently synthesizes a second DNA strand to 
form a double stranded DNA molecule. Integrase then cleaves a dinucleotide sequence from the 3’ ends 
to generate reactive hydroxyl groups primed for integration. The pre-integration complex containing HIV 
integrase, reverse transcriptase and a series of host proteins then shuttles the DNA duplex to the nucleus 
where integrase, with magnesium ions as a cofactor, performs the strand transfer reaction in which the 
reactive hydroxyl groups hydrolyze a phosphodiester bond in actively transcribed regions of the host 
genome. Host cell DNA machinery then repair the single stranded breaks to seal the viral genome into the 
host cell DNA. Next, the inserted viral genome is transcribed into messenger RNA and translated into a 
  
 
polyprotein which is then proteolytically processed by the HIV protease. Mature virus particles are 
assembled followed by budding from the host cells into the plasma to start a new infectious cycle.  
1.3 The HIV-1 genome 
 The HIV-1 genome consists of a long single stranded RNA molecule that is 9.18 kb in length 
containing nine genes, gag-pol, gag, vif, vpr, tat, rev, vpu, env, and nef (Figure 1.2) [10, 11]. The Gag-Pol 
polyprotein is proteolytically cleaved by the protease enzyme to release mature protease, integrase and 
reverse transcriptase; three enzymes required for HIV reproduction. Once processed, cleavage of Gag 
generates the matrix protein (MA, p17), capsid protein (CA, p24), nucleocapsid protein (NC, p7), spacer 
peptide 1 (SP1, p2) spacer peptide 2 (SP2, p1) and p6. The env gene is processed by host proteases to 
generate the external glycoprotein gp120 and the transmembrane glycoprotein gp41 which interact 
noncovalently with each other on the surface of HIV-1 virions [12].  The regulatory proteins Tat and 
regulator of virion (Rev) function primarily in the cell nucleus by stimulating transcription and regulating 
viral RNA production, respectively [13]. The negative regulator protein (Nef) is an accessory protein 
having multiple roles including increasing or decreasing virus replication, reducing expression of MHC 
class I and the CD4 receptor;  T-cell activation; and enhancing virion infectivity [14].  Another accessory 
protein, virion infectivity factor (vif) increases virus infectivity by affecting virion assembly during viral 
replication as it induces degradation of the antiretroviral cytidine deaminase, APOBEC3G [15]. The viral 
protein r (vpr) causes G2 arrest and facilitates nuclear entry of the preintegration complex and viral 
protein u (vpu) affects virus release by disrupting the Env-CD4 complexes on the cell surface[16]. An 
important feature of the HIV-1 viral genome is the presence of the long terminal repeat sequences (LTR) 
on the viral ends which provide recognition sites for the HIV-1 integrase to bind and perform the 
3’processing reaction to be discussed later in section 1.5. 
  
 
 
Figure 1.2 The HIV-1 genome. A. The elements of the HIV-1 viral genome are expressed in three 
different open reading frames as indicated by the vertical spacing. B. The long terminal repeat regions are 
shown to illustrate the di-nucleotide cleavage site indicated by the green arrow. 
 
1.4 Treatment of HIV-1 infection with Highly Active Antiretroviral Therapy 
(HAART) 
 Treatment options for both treatment naïve and treatment experienced HIV patients span five 
different drug classes  including nucleoside/nucleotide reverse transcriptase inhibitors, protease inhibitors, 
fusion and entry inhibitors, non-nucleoside reverse transcriptase inhibitors, and  integrase inhibitors. 
Various combinations of these drug classes comprise Highly Active Antiretroviral Therapy (HAART) 
which has emerged as the current standard of care.  
1.5 HIV-1 protease 
 HIV-1 protease (PR) functions as a homodimer containing 99 residues per monomer. It is an 
aspartic protease required for the maturation of HIV viral proteins and thus the reproduction of infectious 
virions [17]. As a member of the aspartic protease family of protease enzymes, HIV-1 PR uses two 
aspartic acid residues; one from each monomer (Asp25 and Asp25’); to make up the active site for 
catalysis of peptide substrates, Gag and Gag-Pol polyprotein precursor [18] . For this reaction to proceed, 
  
 
one aspartic acid is protonated to serve as a general acid to polarize the scissile carbonyl oxygen of the 
substrate while the ionized form of the opposing aspartic acid is the nucleophile which deprotonates the 
required lytic water molecule (Figure 1.3) [19-24]. During substrate cleavage, the protonated aspartate the 
oxyanion intermediate then hydrolysis the peptide bond thus cleaving the substrate into two peptides. In 
addition to the two aspartic acid residues HIV-1 PR also contains a highly conserved Asp-Ser/Thy-Gly 
sequence motif at the active site which may also play a critical role in substrate binding [25, 26]. The PR 
active site is covered by two flexible β-hairpin loops which open and close to allow substrate binding and 
release [27].  
 
Figure 1.3 Mechanism of HIV-1 substrate cleavage by the protease enzyme.  
1.5.1 Protease inhibitors 
 A major breakthrough in the treatment of HIV/AIDS came with the development of HIV-1 PR 
inhibitors which are currently being used extensively in HAART therapy. The United States Food and 
Drug Administration has approved 9 protease inhibitors; tipranavir, darunavir, amprenavir, lopinavir, 
atazanavir, saquinavir, indinavir, ritonavir, and nelfinavir. With the exception of darunavir, PR inhibitors 
were designed as peptidomimetic compounds to resemble the transitions state between the endogenous 
  
 
substrates and PR based on a series of X-ray crystal structures of the HIV-1 PR bound to several 
inhibitors. These structures revealed key features that became instrumental in the subsequent design and 
development of these inhibitors; (1) HIV-1 PR is a homodimer with C2 symmetry, (2) the catalytic 
aspartic acid residues lie at the bottom of the active site (3) a tetrahedrally coordinated water molecule 
between the HIV-1 PR flaps and the bound ligand may play a role in stabilizing the drug in the active site 
[28, 29].  
 
Figure 1.4. Chemical structure of the FDA approved HIV-1 protease inhibitors 
 
1.5.2 Protease inhibitor mechanism of inhibition 
 Each of the HIV-1 PR inhibitors (PIs) currently on the market contains a hydroxyl group required 
to mimic the transition state of proteolytic cleavage. This reaction proceeds through a gem-diol reaction 
intermediate as observed using 
18
O isotope exchange experiments [30]. This hydroxyl group interacts 
with the D25 and D25’ to inhibit the HIV-1 PR. In addition to this feature, the PIs also bind the PR in a 
  
 
similar fashion in which the P1 and P1’ groups of the inhibitor bind to the S1 and S1’ pockets of the HIV-
1 PR similar to the binding mode seen in substrate binding (Figure 1.5) [31-33]. The inhibitors 
consistently make contacts with Gly, 27, Asp 29, Asp 30 and Gly 48.  
 
Figure 1.5 Binding mode of the substrate in the HIV-1 protease active site. P4-P3’ indicate the position 
of the substrate peptide while S4-S3’ indicate the binding pockets of the HIV-1 protease. The red star 
represents the substrate cleavage site.  
 
1.6 HIV-1 integrase 
 Viral DNA integration mediated by HIV integrase is a key process required for viral replication 
[34]. While in the cytoplasm, integrase assembles into a dynamic complex termed the pre-integration 
complex (PIC), known to consist of the viral proteins; Vpr, matrix, integrase, and reverse transcriptase.  
Vpr has been shown to be involved in modulating the viral reverse transcription, nuclear import of the 
HIV-1 pre-integration complex, and transactivation of the HIV-1 LTR promoter. The HIV integrase 
enzyme catalyzes 3’ processing (3’p); a dinucleotide sequence is cleaved from the 3’ end of the viral 
genome at the long terminal repeat sequences generating reactive hydroxyl ends primed for integration 
[35]. Integrase interacts with cellular proteins importin α and transportin 3 to assist with effective import 
through the host nuclear pore complex [36]. After translocation to the host cell nucleus, HIV integrase 
then facilitates the strand transfer transesterification reaction where the viral DNA is inserted into the host 
chromosome. Concerted integration of the viral DNA is performed by the synaptic complex in which 
  
 
integrase functions as a tetramer, however the monomer has been shown to interact specifically with the 
viral LTR. [37] Insertion of the viral genome is also mediated by the PWWP domain of the cellular 
chromatin interacting protein LEDGF/p75 by tethering and targeting the HIV-1 integrase to regions with 
specific post translational modifications [38]. Upon insertion, host DNA repair pathways are induced 
increasing expression of Rad51, a protein involved in the homologous recombination-directed DNA 
repair (HHR) pathway as well as various other cellular proteins [39]. 
1.6.1 Integrase inhibitors 
 In 2007, raltegravir (RAL) was the first HIV integrase inhibitor to be approved by the US Food 
and Drug Administration (FDA)  Two additional integrase inhibitors, elvitegravir (EVG), and 
dolutegravir (DTG, S/GSK1349572), are currently in clinical trials while other compounds are in 
development.   
Raltegravir 
 Raltegravir was the first strand transfer inhibitor (STI) to be approved by the FDA for the 
treatment of HIV-1 infection. 400 mg twice-daily dosing of RAL with once-daily tenofovir-emtricatabine; 
a reverse transcriptase inhibitor,  is one of the preferred treatment options for treatment-naïve HIV-1 
infected patients, while once daily dosing of RAL was not recommended for increased risk of the 
development of drug resistance resulting in treatment failure [40]. 
 RAL was optimized from two scaffolds; dihydroxyperimidine and N-methyl pyrimindinone 
carboxamides, both of which had been shown to inhibit strand transfer [41]. RAL is metabolized by 
UGT1A1. While the increase in plasma concentration of RAL caused by co administration with a 
UGT1A1 inhibitor was not found to be clinically meaningful, the decrease caused by a UGT1A1 inducer 
is being investigated in clinical studies [42]. The site of RAL action is intracellular, however studies 
showed that RAL penetration into cells is approximately 5% of plasma levels with high variability 
between patients [43].  
  
 
 
Figure 1.6 Chemical structure of FDA approved HIV-1 integrase strand transfer inhibitors. Oxygen 
atoms involved in metal chelation are shown in red. 
 
Elvitegravir 
 Elvitegravir (GS9137) is an integrase inhibitor approved as part of a “Quad” formulation pill 
containing EVG, emtracitabine, tenofovir disoproxil fumerate and cobicistat (GS0350) which has the 
advantage of once daily dosing [44, 45]. The structure was derived from chemical modification of 
quinolone antibiotics containing a monoketo acid motif capable of integrase inhibitory efficacy 
comparable to the diketo acid structural motif [46].  EVG has been observed to possess post antiviral 
effects in cultured CD4-positive cells suggesting a possible role as a potential prophylaxis application 
[47]. EVG was shown to inhibit the ABC transporter, ABCB1 in P388/dx and L-MDR1 cells suggesting 
that EVG may play an important role in resistance and drug-drug interactions [48]. 
  
 
Dolutegravir 
 Dolutegravir (S/GSK1349572) is a potent second generation STI currently in phase III clinical 
trials with a cell-based therapeutic index of 9,400 showing efficacy against NNRTI, NRTI, and PI-
resistant viruses with activity equivalent to that against the wild-type virus [49]. Its pharmacokinetic 
profile, short-term tolerability and potent antiviral activity support once-daily dosing as demonstrated in 
treatment –naïve HIV patients [50]. According to crystal structures with the prototype foamy virus (PFV), 
DTG binds the active site of the retroviral intasome with its three coplanar oxygen atoms coordinated to 
the active site Mg
2+
 cations and the halogenated phenyl group displaces the 3’ terminal viral DNA [51]. 
DTG has a 5 to 40 times slower dissociation constant than RAL and EVG in the integrase-DNA complex 
[52].  
1.6.2 Integrase inhibitor mechanisms of inhibition 
 HIV-1 integrase inhibitors currently on the market work by competing with viral DNA for active 
site binding to inhibit the strand transfer step of the HIV life cycle. Alternatively, allosteric inhibitors are 
being developed which modulate integrase activity by affecting assembly, or interfering with binding to 
host cell factors. 
  
 
 
Figure 1.7 Mechanism of action of HIV-1 integrase strand transfer inhibitors 
1.6.2.1 Strand transfer inhibitors  
 Integrase strand transfer inhibitors (STIs) bind to the HIV-1 integrase enzyme in complex with its 
viral DNA and two divalent metal ions (Figure 1.7) [53]. The ability of an STI to physically trap the 
synaptic complex and therefore inhibit concerted integration correlates with its inhibitory efficacy, IC50 
[54]. The metal chelating functionality of integrase STIs may be involved in multiple processes such as 
the exchange of metals in the active site and the coordination of a second metal; suggesting a mechanistic 
explanation of some molecules’ ability to inhibit 3’ processing in addition to strand transfer. The 
halogenated phenyl group plays a vital role in displacing the viral terminal DNA residue from the active 
  
 
site [55, 56]. Before the structure of the PFV intasome had been published a number of molecular 
modeling studies provided insights on possible binding modes and mechanisms of action. Induced fit 
docking experiments with the integrase inhibitors L-708,906, L-731,988, S-1360, L-870,810, raltegravir, 
and EVG showed consistent support of the proposed metal chelating mechanism. [57] Inhibition kinetics 
studies of these inhibitors as well as GSK364735 indicate time-dependent inhibition consistent with a two 
step binding mechanism [58]. 
1.6.2.2 Allosteric inhibitors 
 Allosteric integrase inhibitors are designed to either disrupt subunit assembly, indirectly disrupt 
DNA-binding site conformation or disrupt obligatory protein-protein interactions [59]. The N-terminal 
domain of integrase contains a highly conserved HHCC zinc binding motif that enhances multimerization 
and is also involved in DNA binding [60, 61]. Disruption of the HHCC domain renders intergrase 
incapable of catalytic activity and of initiating reverse transcription making the virus non-infectious [62-
64].  Crystal structures of cyclic peptides bound to the HIV-1 integrase catalytic core domain identified 
residues 170, 171, and 174 as potential targets to inhibit the LEDGF/p75 interaction [65]. Molecules such 
as PLP targeting the C-terminal domain have revealed its importance in DNA binding as viruses carrying 
the K244E substitution are deficient in 3’processing and strand transfer activity [66]. A number of 
compounds have been identified to reveal allosteric binding sites on the dimeric interface disrupting 
oligomerization [59].   
1.7 Antiretroviral resistance 
 While there are many different types of antiretrovirals (ARV) used in the treatment of HIV, the 
development of drug resistance resulting in treatment failure remains a major challenge. To combat the 
resistance problem, the development of molecules with a new mode of action or active substituent and 
improved potency are needed. 
  
 
1.7.1 Protease inhibitor resistance 
 Multi-drug resistance mutations in the HIV-1 PR selected under PI treatment occur which reduce 
the effectiveness of the PI. Common mutations conferring cross resistance to the PI class of inhibitors 
include V32I, L33F, M46IL, I47VA, G48VM, I50LV, I54VTALM, L76V, V82ATFS, I84V, N88S, and 
L90M (Figure 1.8)  [67, 68].  While most of the PIs have a similar resistance profile, darunavir and 
tipranavir seem to have a higher barrier to resistance with increased resilience against these common 
mutations [69].  
 
Figure 1.8 Major drug resistant mutations cluster around the active site of HIV-1 protease. The major 
drug resistant mutations are shown in red sphere representation. The catalytic residues D25 and D25’ are 
shown in blue stick model. 
 
Atazanavir resistance  
 Ritonavir boosted atazanavir in combination with tenofovir and emitricitabine, two nucleoside 
reverse transcriptase inhibitors, is currently one of the first line treatment options for initial treatment of 
HIV/AIDS patients [70].  The following mutations have been observed in patients and contribute to 
  
 
reduced susceptibility in combination with other PI resistance mutations; V32I, L33F, M46IL, I47V, 
I54VTALM, and V82ATFS [71, 72]. G48VM and L90M mutations reduce susceptibility and virological 
response while I50L, I84V, and N88S are associated with the highest levels of reduced susceptibility to 
atazanavir [73-75].    
Darunavir resistance 
 Ritonavir boosted darunavir containing regimens are also included in the preferred treatment 
guidelines[70]. Darunavir has the most favorable drug resistance profile in that mutations I47VA, I50V, 
I54LM and L76V are associated with reduced susceptibility as opposed to virological failure as seen with 
the other protease inhibitors [76, 77].  
Fosamprenavir resistance 
 Fosamprenavir is the only pro-drug HIV-1 protease inhibitor with efficacy comparable to 
lopinavir [78]. As a pro-drug its long acting nature allows for less frequent dosing making it an attractive 
option for patients with compliance issues. Resistance to fosamprenavir occurs with mutations V32I, 
I47VA, I50V, I54VTALM, L76V, V82ATSF, I84V, and L90M resulting in significantly reduced 
susceptibility and virological response.  Despite the cross resistance profile of fosamprenavir, dual 
boosted protease inhibitor-based regimens containing atazanavir and fosamprenavir may be effective 
against treatment experienced pediatric patients [79].  
 Indinavir resistance 
 Resistance mutations resulting in the highest levels of virological failure under indinavir selection 
pressure include I54VTALM, L76V, V82AFTS, and I84V. While not in the first line treatment options; 
indinavir remains susceptible to protease populations containing the common I50LV mutation which are 
resistant to atazanavir, darunavir and lopinavir [76, 80]. Indinavir is quickly metabolized by liver 
enzymes and has been shown to result in kidney failure due to its hepatotoxicity [81]. Both the side effect 
  
 
profile and the dosing schedule play a major role in the development of drug resistance due to patient 
compliance. 
Lopinavir resistance 
  Lopinavir is the first line treatment option for pregnant women and children due to its safety and 
efficacy in pediatric HIV-1 treatment [70].  A long-term clinical study performed in the UK showed that 
27% of patients on lopinavir containing regimens experienced virological failure after one year in which 
I54V, M46I, V82A and L76V were the most frequently occurring mutations [82].  
Nelfinavir resistance 
 Nelfinavir resistance is seen with mutations similar to the other PIs. However, nelfinavir is the 
only protease inhibitor which results in reduced virological response as a result of the D30N mutation. 
The precise structural mechanism resulting in failure with nelfinavir is not well understood, however 
molecular dynamics simulations with HIV-1 protease enzymes of different subtypes suggest that D30N 
may be responsible for conformational changes associated with the loss of secondary structure in the HIV 
PR [83].  The accessory mutation K20I has been shown to contribute to reduced susceptibility in B-
subtypes [84]. 
Saquinavir resistance 
 Saquinavir resistance is acquired with the major mutations G48VM, I54VTALM, V82AT, I84V, 
N88S and L90M. While many accessory mutations contribute to reduced susceptibility against other PIs, 
the I47A mutation actually increases susceptibility to saquinavir [85]. Interestingly this mutation reduces 
susceptibility to lopinavir. The structural mechanisms underlying these differences in PI efficacy have yet 
to be explored.  
Tipranavir resistance 
 Like darunavir, tipranavir has a high barrier to resistance with a similar resistance profile. 
Complications with tipranavir however are due in part to the high risk of intracranial hemorrhage and 
  
 
liver-associated deaths [86-88].  Tipranavir has demonstrated reduced susceptibility against drug resistant 
proteases harboring V30I, L33F, M46IL, I47VA, I54VAM, V82TL, and I84V. Interestingly, tipranavir 
remains effective against the common multidrug resistant mutations G48VM, I50LV, L76V, N88DS, and 
l90M. 
1.7.2 Integrase inhibitor resistance 
Raltegravir resistance 
 Patients failing on RAL containing regimens frequently carry viruses harboring primary 
mutations at codons 148, 155 and 143 [89]. The G140S mutation has been shown to increase viral fitness 
while the Q148H mutation is likely responsible for resistance to RAL as the double mutation displays 
replication capacity near wild-type levels [90].  The Q148H, G140S double mutation also confers cross 
resistance to EVG and G-quadruplex inhibitors [91]. Cocrystal structures of S217Q, S217H and N224H 
mutant PFV intasomes corresponding to HIV-1 integrase RAL resistance mutations Q148H and N155H 
in complex with the second generation STI MK2048, showed that these substitutions interfere with metal 
coordination [92]. Based on the mechanism of STI action, any loss in metal coordination would 
subsequently decrease the chelating power of the inhibitor.  RAL resistance may also occur through 
transmission of multi drug resistant variants highlighting the importance of genotyping even in treatment 
naïve patients [93].  
 Viral strains harboring the 148H/140S mutations have a ten-fold reduction in susceptibility to 
MK-2048 and the S153F/Y mutations confer resistance to MK-2048 as well as GSK-1349572 suggesting 
a common mechanism between these two molecules [94]. The secondary mutation T97A rescues the 
catalytic defect caused by the RAL primary resistance mutation, Y143R/C, and reduces in vitro 
susceptibility to RAL [95]. The second generation STI MK-0536 binds to HIV-1 IN CCD with nanomolar 
inhibitory efficacy and increased potency against classical RAL resistance mutations [96]. 
  
 
 
Figure 1.9. Resistance mutations in HIV integrase. HIV-1 IN CCD (50-212) raltegravir resistance 
mutations associated with 5-10 fold decreased susceptibility are shown in red, Mg
2+
 in magenta, and 
catalytic residues in blue. 
 
Elvitegravir resistance 
 EVG is a potent STI, however resistance mutations have been observed with primary mutations at 
T66I, E92E/Q, Q146P, and S147G and secondary mutations H51Y, Q95K, E138K, and E157E/Q 
[97].The T66I/A mutation was observed most frequently among patients experiencing virologic failure on 
EVG containing regimens during phase 3 clinical trials [98]. Additional EVG resistance mutations F121Y 
and S153F/Y have also been observed to cause cross resistance to other STIs [99-101].  While EVG 
overcomes resistance to the RAL mutation Y123C/R, the 148 and 155 pathway of RAL resistance confers 
cross resistance to RAL [102]. 
Dolutegravir resistance 
 No treatment-naïve patient has developed resistance to DGV, however the mutations involving 
T134A, S153F/Y, and L101I mutations have been observed in vitro[49, 52]. In vitro DTG selection 
experiments revealed the R263K mutation that causes low-level resistance to DTG as well as reduced 
viral fitness due to the specific reduction DNA binding [103]. DTG has been shown to be effective 
  
 
against first generation STIs RAL and EVG mutations at Y143 and N155H however the Q148H/R in 
combination with G140S/A pathway confers reduced susceptibility to DTG as well and early 
discontinuation of RAL is necessary for treatment with DTG as a rescue therapy for patients who have 
experienced virological failure [104, 105].  
 
Figure 1.10 Structure-based drug design. The goal of this work is to use structural information to design 
better inhibitors for the treatment of multi-drug resistant HIV-1 infection. 
 
1.8 Structure-based drug design 
 Historically, drugs were discovered by identifying active components of traditional remedies; 
however more recently drugs have been discovered or optimized using a structure-based approach (Figure 
1.9). Quantitative drug design is a method which relates the biological properties of a compound as a 
function of its physiochemical parameters such as solubility, lipophilicity, electronic effects, ionization, 
and stereochemistry [106]. The original Hansch equation of the form: 
log (1/C) = k1log P – k2(log P)
2
 + k3σ + k4 
  
 
Where C is the concentration of the compound required to produce a standard response in a given time, 
log P is the logarithm of the partition coefficient of the compound between 1-octanol and water (which 
was chosen as a suitable measure of relative hydrophobicity), σ is the Hammett substituent parameter and 
k1- k4 are constants; relating a molecule’s electronic characteristics to hydrophobicity was used to define 
these parameters [29, 107-109]. This concept of quantitative structure activity relationships (QSAR) has 
since been adapted to reflect a number of different relationships. Of particular interest to the design of 
protease inhibitors, the use of relative shape of the substrate envelope has proven to be effective [28, 31, 
110].  Using structural information from x-ray crystallography, NMR and molecular modeling, the 3D-
QSAR methodology makes it possible to identify specific interactions between the ligand and the 
enzyme.  Therefore, optimizing these interactions to increase binding affinity can potentially increase the 
potency of an inhibitor. 
  
 
Chapter 2: Materials and Methods 
2.1 HIV-1 protease expression and purification 
Active and inactive MDR HIV-1 protease genes were codon optimized for E. coli expression with 
the software DNA 2.0 [111], synthesized by GENEART, Inc. (Regensburg, Germany), and inserted into 
the pET21b plasmid. The inactive MDR 769 82T protease carries an active site mutation, D25N, to 
eliminate catalytic activity. To prevent auto-proteolyses, the Q7K mutation was introduced into the active 
MDR HIV-1 protease gene. All MDR HIV-1 proteases were expressed in the E. coli strain BL21 (DE3) 
pLysE and the cells were lysed by sonication. The HIV-1 protease expressed in inclusion bodies was 
separated by centrifugation and dissolved in a buffer of 50 mM Tris, 25 mM sodium chloride, 0.2% β-
mercaptoethanol, and 6 M urea. The dissolved HIV-1 protease variants were purified using a Q-Sepharose 
ion exchange column (Amersham Biosciences, Piscataway, NJ) pre-equilibrated with the buffer 
containing 6 M urea. The optimal buffer pH varied from 7.8-8.6 for the active and inactive protease 
variants. The flow-through containing the pure HIV-1 protease was refolded in the dialysis buffer (20 mM 
sodium phosphate, 0.2% β-mercaptoethanol, and 10% glycerol) with step-wise decreases in urea 
concentration. The final protein buffer was 20 mM sodium acetate, pH 5.0, 1 mM dithiothreitol (DTT), 
and 10% (v/v) glycerol. The proteases prepared for crystallization were concentrated to 1.5 mg/ml using 
Amicon concentrators with a 5-kDa molecular mass cut-off (Millipore Corporate, Billerica, MA). 
2.2 Protease inhibition assays 
HIV protease Forster Resonance Energy Transfer (FRET) substrate I, purchased from AnaSpec, 
Inc. (Fremont, CA, USA), was used in the half-maximal inhibitory concentration (IC50) determination 
experiments. The FDA-approved HIV-1 protease inhibitors were kindly provided by the NIH AIDS 
Research and Reference Reagent Program (www.aidsreagent.org). The CA/p2 pseudopeptide with a 
reduced scissile peptide bond [-ψ(CH2NH)-] was synthesized in the laboratory of Patrick Woster in the 
Department of Chemistry, Wayne State University. The fluorescence emitted by substrate cleavage was 
  
 
monitored by a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) at a 340 nm 
excitation wavelength with an emission wavelength of 490 nm. The HIV-1 protease reaction buffer was 
adjusted to pH 4.7 [0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM ethylenediaminetetraacetic 
acid (EDTA), 1.0 mM DTT, 10% dimethylsulfoxide (DMSO), and 1mg/ml bovine serum albumin 
(BSA)]. In the reaction buffer containing 5 μM FRET substrates, the concentration of all the HIV-1 
proteases used in the enzyme assays was adjusted to a substrate cleavage velocity of 0.08 Relative 
Fluorescence Units (RFU)/sec. The final HIV-1 protease concentration was approximately 7 nM. The 
protease inhibitor was serially diluted in DMSO from 10 μM to 0.013 nM. The protease and inhibitors 
were pre-incubated at 37°C for 20 min prior to signal monitoring. An enzyme-free control was tested as 
the background substrate fluorescent signal. The progress of the reaction was monitored over 20 min 
sampling fluorescence at 1 min intervals. The FRET data were plotted with the software SoftMax Pro 
V5.2 (Molecular Devices, Sunnyvale, CA) using a 4 parameter fit to determine the IC50 values.  
2.3 Crystallization and diffraction data collection 
Reduced substrates (F-r-L and F-r-F) were co-crystallized with the MDR769 82T inactive protease 
using the hanging drop vapor diffusion method. The protease and ligand were pre-mixed at a molar ratio 
of 1:20 before crystallization set-up. The protease-ligand solution was then mixed at 2:1 v/v ratio with the 
precipitant solution. The optimal crystallization condition was obtained from for the MDR 769 82T-/F-r-
L complex from 0.1 M citric acid and 2.4 M ammonium sulfate at pH 5.2 while the MDR 769 82T-/F-r-F 
complex crystallized with 0.1M MES, 2.4 M (NH4)2SO4, pH 6.2. The reservoir volume was 750 μl. 
Needle shape crystals grew to a suitable size for diffraction within a week. The crystals were placed in a 
30% w/v glucose cryoprotectant solution before the crystals were frozen in liquid nitrogen. The 
diffraction data were collected at the Life Sciences Collaborative Access Team (LS-CAT) at the 
Advanced Photon Source (APS) Sector 21, Argonne National Laboratory (Argonne, IL, USA) and the 
diffraction data were processed with the HKL2000 program suite [112].  
  
 
2.4 Structure refinement and analysis 
Molecular replacement was performed with the CCP4 program Molrep-autoMR [113]. A previously 
solved HIV-1 protease structure was used as a searching model for molecular replacement. The models of 
the reduced substrate peptides were built with the program COOT [114] using a ligand finding algorithm 
where the molecular formulas of the inhibitors were provided in SMILES representation. The protease-
ligand model was further refined using the program Refmac5. The structure was validated using Procheck 
V3.4.4 [115]. The co-crystal structures were deposited in the Protein Data Bank (http://www.pdb.org/). 
The accession codes for the L-r-F-MDR 769 82T complex and the F-r-F-MDR 769 82T complex are 
4GZF and 4GYE, respectively. 
2.5 Molecular dynamics 
 Molecular dynamics (MD) is a computational method to calculate the time dependent behavior of 
a molecular system by numerically solving Newton’s equations of motion using a molecular mechanics 
force field which defines the forces between charges as well as the potential energy function. Internal 
motions of proteins cause conformational changes that play an essential role in protein function [116]. 
These simulations provide detailed structural information regarding local motions such as atomic 
fluctuations, side chain motion and loop motions. MD simulations on the scale of nano seconds to 
seconds may demonstrate larger protein dynamics such as helix, domain and subunit motions. Large-scale 
motions greater than 5 Å, including helix coil transitions, dissociation/association and folding and 
unfolding behaviors may take minutes to be observed in an MD simulation [117-120].   
2.5.1 The CHARMM force field 
 All computational work presented here has been performed using the CHARMM (Chemistry at 
HARvard Macromolecular Mechanics) force field originally developed at Harvard in the laboratory of 
Martin Karplus and continues to be updated regularly [121, 122]. The components of the potential 
account for bond stretching, bond angle bending, torsion (dihedral angle), and nonbonded interaction. 
  
 
The nonbonded interactions include van der Waals (vdW) energy and electrostatic (Coulomb) 
energy. The potential energy and its derivatives are calculated from the coordinates corresponding to the 
structure or conformation based on fixed point charges as shown in Equation 1 below [122]. 
(Eq 1.) 
The potential energy, (U(R )), is a sum over individual terms representing the internal and non-bonded 
contributions as a function of the atomic coordinates. Internal terms include bond (b), valence angle (θ), 
Urey-Bradley (UB, S), dihedral angle (φ), improper angle (ω), and backbone torsional correction (CMAP, 
φ,ψ) contributions. The parameters Kb, K φ, KUB, Kθ and Kω are the respective force constants and the 
variables with the subscript 0 are the respective equilibrium values; here n is the multiplicity or 
periodicity of the dihedral angle and δ is the phase shift. 
2.5.2 Scalable molecular dynamics with NAMD 
The MD simulations were performed using the parallel computing program Scaling NAno 
Molecular Dynamics (NAMD) V. 2.7b [123]. The protease complex models were solvated in a water box 
using TIP3P models for water molecules. To prevent translational and rotational displacement and to 
prevent the simulation of the catalytic reaction, positional restraints were applied for the carbonyl 
protease. The cutoff of non-bonded interactions was 10 Å. Particle Mesh Ewald was implemented to 
calculate long-range electrostatic interactions [124]. The systems were energy minimized using a 
conjugate gradient method and gradually heated from liquid nitrogen temperature of 70K to 310K in 200 
ps. Simulations were conducted in the isobaric-isothermal ensemble at 310K and 1.0 atm (NPT ensemble) 
  
 
for 10-40 ns using the CHARMM force field 27 or the CHARMM force field 36 and a timestep of 2 fs to 
ensure all the all conformers are sampled during the simulation. 
All simulations were performed in the NPT ensemble. Langevin dynamics was used to keep the 
system at a constant temperature of T = 310K. The Langevin damping coefficient was set to 5 ps
-1
.  
Constant pressure was maintained using the Nose-Hoover Langevin piston method at 1 atm. [125, 126] 
MD simulations were performed in parallel on multiple processors using the Wayne State University high 
performance scientific computing Grid (www.grid.wayne.edu). The WSU Grid has the combined 
processing power of 1558 cores: 898 Intel cores, 660 AMD Opteron cores, with over 2TB of RAM and 
over half a petabyte of disk space. 
An example of NAMD configuration commands with annotations is listed as follows. 
## Adjustable Parameters 
structure  input.psf ; # Specify a protein structure file that contains molecular  
                                                   characteristics required by a particular force field.  
coordinates  input.pdb ; # Specify an atomic coordinate file 
set temperature 310 ; # The simulation was conducted at 310 K. 
set outputname  output ; # Name the output files 
firsttimestep  0 ; # Start the simulation from step 0. 
## Simulation Parameters 
paraTypeCharmm on ; # Turn on CHARMM force field. 
parameters Par_all27_prot_na.prm ; # Specify the CHARMM27 parameter file which define 
      forces and energies for protein, lipid, DNA, and RNA. 
parameters par_all36_cgenff.prm ; # Specify the CHARMM General Force Field parameter  
    file for compounds. 
temperature $temperature ; # Read temperature from “temperature” variable. 
reassignFreq  2000 ; # Reassign temperature every 2000 steps. 
  
 
reassignTemp 70 ; # Increase temperature from 70 K (the liquid nitrogen temperature). 
reassignIncr  5 ; # The temperature increment is 5 K. 
reassignHold  310 ; # Hold the temperature at 310 K. 
# Force-Field Parameters 
exclude scaled1-4 ; # Four adjacent covalently bonded atoms are excluded from non-bonded  
    calculations. 
1-4scaling 1.0 ; # The constant factor of electrostatic interactions for 1-4 atom pairs. 
cutoff  12. ; # The cutoff distance for non-bonded interaction is 12 Å. 
switching on ; # Smoothing functions are applied to both the electrostatics and van der  
   Waals forces. 
switchdist 10. ; # The smoothing function takes effect when atom distance is between 10  
   and 12 Å. 
pairlistdist 13.5 ; # When distance between atoms is less than 13.5 Å in each cycle, the  
   atom pair is included in pair list for electrostatics and van der Waals interaction  
   calculation. 
margin  2.5 ; # Add 2.5 Å length in patch dimension. 
# Integrator Parameters 
timestep 2.0 ; # The length of each step is 2fs. 
rigidBonds all ; # The bond between hydrogen and its bonded atoms is constrained. 
nonbondedFreq 1 ; # Non-bonded interactions are calculated in every time step. 
fullElectFrequency 2 ; # Full electrostatic interactions are calculated in every 2 time step. 
stepspercycle 10 ; # The interacting particle lists are updated every 10 time step. 
# Constant Temperature Control 
langevin on ; # Perform Langevin dynamics to introduce additional damping and random  
   forces to the system. 
  
 
langevinDamping 5 ; # Langevin damping coefficient is 5/ps 
langevinTemp $temperature ; # Langevin dynamics adjust the effect on atoms based on the  
   temperature variable. 
langevinHydrogen off ; # Turn off Langevin dynamics for hydrogen atoms. 
# Constant Pressure Control 
useGroupPressure yes ; # Pressure is calculated using hydrogen-group based pseudo- 
    molecular virial and kinetic energy which results in smaller fluctuations. 
useFlexibleCell  no ; # Do not allow three orthogonal dimensions of the periodic cell to f 
    luctuate independently. 
useConstantRatio no ; # Do not maintain a constant ratio of the unit cell in the x-y plane. 
langevinPiston  on ; # Turn on Langevin piston pressure control. 
langevinPistonTarget 1.01325 ; # The target pressure is 1.01325 bar. 
langevinPistonPeriod 100 ; # The barostat oscillation time scale is 100 fs. 
langevinPistonDecay 50 ; # The barostat damping time scale is 50 fs. 
langevinPistonTemp $temperature ; # The barostat noise temperature is the same as the  
    temperature specified in temperature control. 
# Output 
outputName $outputname ; Specify the output name for output files. 
restartfreq 1000 ; # Prepare the restart files every 1000 steps (2 ps). 
dcdfreq  1000 ; # The trajectory file is updated every 1000 steps. 
outputEnergies 1000 ; # Output energy to log file every 1000 steps. 
outputPressure 1000 ; # Output pressure to log file every 1000 steps. 
#Harmonic constraints 
constraints on ; # Turn on positional restraints. 
Consex p 2 ; # Use 2 as an exponent for constraint energy function 
  
 
conskcol B ; # Specify the B factor column of the PDB file to use for the harmonic  
    constraint force constant. 
consref constraint.pdb ; # Input the PDB file indicating constraint atoms. 
conskfile constraint.pdb ; # Input the PDB file to use for force constants for harmonic  
   constraints. 
## Extra Parameters 
# Periodic Boundary Conditions  
cellBasisVector1 80.16 0.0 0.0 ; # Specify the x-dimension of the periodic cell size in Å. 
cellBasisVector2 0.0 63.51 0.0 ; # Specify the y-dimension of the periodic cell size in Å. 
cellBasisVector3 0.0 0.0 64.93 ; # Specify the z-dimension of the periodic cell size in Å. 
cellOrigin  5.26 1.74 16.96 ; # Specify the position of the periodic cell center. 
wrapWater  on ; # When water molecules cross a periodic boundary, they are not  
    translated to the other side of the periodic cell. 
wrapAll  on ; # When a molecule cross a periodic boundary, it is not translated to  
    the other side of the periodic cell. 
# PME Particle Mesh Ewald 
PME yes ; # Turn on Particle Mesh Ewald method, an efficient full electrostatics method in  
   periodic boundary conditions. 
PMEGridSizeX 90 ; # Number of grid points in X dimension. 
PMEGridSizeY 72 ; # Number of grid points in Y dimension. 
PMEGridSizeZ 72 ; # Number of grid points in Z dimension. 
## Execution Script 
# Minimization 
minimize 10000 ; # Run 10,000 step conjugate gradient energy minimization. 
  
 
reinitvels $temperature ; # Reset the temperature according to the temperature variable  
   after minimization 
# Molecular Dynamics 
run 7500000 ; #Run molecular dynamics for 7500000 steps, equal to 15000 ps (15 ns) 
2.5.3 Initial model preparation for molecular simulation 
The X-ray structures of the protease-substrate complex (MDR 769-CA/p2 co-crystal structure) is 
solved and used as an initial structure for homology modeling using SWISS-MODEL [127]. Based on the 
catalytic mechanism of HIV-1 protease, Asp 25 was assigned as a protonated state while Asp 25’ was 
assigned as a deprotonated state. All histidine residues were assigned a neutral charge. Protonation states 
of other amino acid residues were assumed based on the buffer pH in the HIV-1 protease enzymatic 
assays (pH 4.7). To avoid simulating catalytic interactions, positional restraint was applied to the scissile 
peptide bond of the substrate and β-carboxyl group of catalytic residue Asp 25 and Asp 25’.  
The catalytic core domain structure of HIV-1 integrase was obtained from the Protein Data 
Bank[128] with PDB entry 1BL3[129]. While this structure contains chains A, B and C, chain A was 
used as a template to generate a homology model for each mutant using The Swiss-Model Workspace 
[127]. Crystallographic waters were added to the system by merging the coordinates from the original 
PDB into the new model. Magnesium ions were inserted into the active site as described previously [130]. 
The inhibitor RAL was uploaded to ParamChem (www.paramchem.org) to generate parameter files for 
the inhibitor. RAL was then manually docked into the active site of the IN core in PyMol [131] based on 
the bis-chelation motif of RAL and previously reported modeling structure of the HIV-1 intasome. [132] 
(Fig. 2). The complex was placed into a 62 x 68 x 69 Å
3
 TIP3P water box and magnesium chloride atoms 
were added to neutralize the system. The magnesium ions in the active site and the two coplanar oxygen 
atoms of RAL were given positional restraints while to reduce bias over the metal coordination scheme 
throughout the simulation. The system was prepared in VMD [133]. 
Crystallographic water molecules were retained in each simulation.  
  
 
2.5.4 Analysis of molecular dynamics ensembles 
Trajectories of MD simulation were visualized and analyzed using the Visual Molecular 
Dynamics (VMD) program V. 1.91. The superposition of molecular structures was carried out using 
Pymol. The root-mean-square deviation (RMSD) values were calculated using the VMD RMSD 
trajectory plug-in with the post equilibration frame used as a reference. The molecular mechanics energy 
was calculated using the NAMD energy plug-in in VMD. The final molecular mechanics energy is the 
average of molecular mechanics energy of the last 100 frames (the last 200 ps simulation). Previous 
studies demonstrated that HIV-1 protease ligands show single-maxima probability density function of 
energy [134]. Therefore, the last 200 ps simulation represents a relatively stable protease-ligand complex 
conformation. Hydrophobic solvation energy and electrostatic solvation energy were calculated and 
averaged based on the 10 snapshot coordinates of the last 200 ps simulation.  
The trajectory from NAMD was loaded into VMD. The averages of two independent 10ns MD 
trajectories were used for the RMSD analysis. The RMSD trajectory tool was used to generate RMSD 
data for backbone atoms in the protein of each complex. φ,ψ angles and Ramachandran plots were 
calculated using the Ramachandran analysis tool in VMD independently for each simulation. The figures 
shown here are representative of both simulations. Structure figures were prepared in PyMol. 
2.6 In silico ligand docking and scoring with SwissDock 
 Using computational techniques combined with knowledge-based design approaches can be used 
to do a virtual screen to predict binding properties to a receptor for lead optimization [135]. Drug design 
studies performed here were analyzed using automated docking with the SwissDock Online Server to 
predict binding properties of the inhibitors. 
SwissDock is a protein-small molecule docking web service based on EADock DSS with a user 
friendly interface that allows for rapid and accurate prediction of binding modes[136].  In a test set of 251 
complexes, 57% of  the top-scoring binding modes were within 2 Å RMSD to the crystal structure and 
70% when considering the top five scoring predictions [137]. The MDR 769 HIV-1 protease crystal 
  
 
structure in complex with darunavir (PDB 3SO9), tipranavir (3SPK), and the wild-type HIV-1 protease in 
complex with darunavir (PDB) were used as the target input. The server prepares the input PDB file by 
converting it to CHARMM format, adding hydrogen atoms in accordance with physiological pH, and 
performs 100 steps of energy minimization using the steepest decent method.  Modified lopinavir analogs 
were drawn in ChemDraw and converted to a three dimensional structure .mol2 file format in 
ChemBioDraw3D and uploaded to the SwissDock to perform energy minimization of  the ligand using 
the Merck Molecular Force Field (MMFF) [138-143]. SwissDock server performs the docking in four 
steps; first, many binding modes are generated while their CHARMM energies are simultaneously 
estimated on a grid. Next the binding modes with the most favorable energies are evaluated with FACTS 
(Fast Analytical Continuum Treatment of Solvation) and clustered [144]. Lastly, the most favorable 
clusters can be visualized online and downloaded as a Dock4 file.  The SwissDock server provides an 
output of ranked poses which were visualized in UCSF Chimera and rescored based on their predicted ΔG 
values as well as visual inspection of the ligand [145]. Molecular graphics and analyses were performed 
with the UCSF Chimera package, developed by the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311). 
  
 
Chapter 3: Ligand modifications to reduce the relative resistance of 
multi-drug resistant HIV-1 protease 
3.1. Introduction 
HIV-1 protease (PR) is a 99 amino acid residue aspartic protease responsible for processing the 
HIV-1 viral polyprotein, thus providing the structural proteins, capsid, matrix and nucleocapsid as well as 
the essential viral enzymes PR, reverse transcriptase, and integrase [146].  Since its discovery, PR has 
become an interesting target for the development of antiretroviral drugs. There are currently 9 compounds 
approved by the Food and Drug Administration (FDA) as protease inhibitors (PIs) for the treatment of 
HIV/AIDS. Most PIs are asymmetric substrates which essentially disrupt the symmetric structure of the 
HIV protease (PR), during the blockage of the protease active site. Two of these inhibitors; lopinavir 
(LPV) and ritonavir (RTV); however are identical about the P1/P1’ positions. The molecular mechanism 
for the disruption of PR symmetry and the mechanism by which drug resistant variants are able to combat 
these inhibitors however remains unclear [147].  Co-crystal structures of the MDR HIV protease with the 
endogenous substrate cleavage site peptides reveal an expanded substrate envelope in the MDR PR 
compared to the wild type with significant deviation of the N-terminus from the WT envelope [31].  The 
asymmetric expansion of the MDR PR active site cavity is likely to play a role in the reduced efficacy of 
PIs against these variants [148]. 
Developing novel HIV-1 protease inhibitors that overcome drug-resistance is still a challenging 
task. In drug development, it is difficult to keep pace with the emergence of drug resistance. Compared to 
de novo drug design, drug modification and optimization could lower the risk of failure in clinical trials. 
The modification of available protease inhibitors according to the MDR HIV-1 protease isolate may 
provide a solution to overcome drug resistance. LPV is a second-generation protease inhibitor, derived 
from ritonavir. The smaller P2 and P2’ groups of LPV decrease the contact with highly variable residues 
at the 82 site of HIV-1 protease and improve the inhibitory efficacy against drug-resistant mutants of 
  
 
HIV-1 protease [149].  The P1 and P1’ groups of LPV also involved in the interactions with the protease 
82 site. Therefore, non-identical P1/P1’ modified LPV could be more tolerant to the 82 site variants.  
The MDR HIV-1 protease isolate 769, exhibits cross resistance to HIV-1 protease inhibitors 
[150]. The presence of the I10V mutation in the MDR 769 variant induces alternative conformations of 
the 80’s loop, playing a unique role in disrupting the S1/S1’ binding pockets  Though LPV inhibits MDR 
769 with low relative resistance, further modification of LPV may improve its efficacy against drug 
resistance mutations in the HIV protease. The P1 and P1’ groups of the HIV-1 protease substrate CA/p2 
possessing a reduced scissile peptide bond have been mutated and tested for HIV-1 protease inhibition. 
The current first line protease inhibitor, darunavir, also contains the non-identical combination of leucine 
side chain and phenylalanine side chain at the P1’ and P1 sites [151]. However, LPV carries the 
symmetric P1 and P1’ groups mimicking the phenylalanine side chain. The P1/P1’ ligands, LPV, Leu-
LPV, CA/p2 F-r-F, and CA/p2 L-r-F are shown in figure 3.1. Therefore, by changing the P1 site of LPV 
from a phenylalanine side chain to a leucine side chain (isobutyl group), the inhibitory potency of the 
modified LPV may increase and the relative resistance against MDR protease may decrease. 
 
Figure 3.1 Chemical structures of CA/p2 F-r-F, Lopinavir, CA/p2 L-r-F, Leucine lopinavir 
  
 
Compared to a phenylalanine-phenylalanine combination at P1 and P1’ sites, the combination of 
leucine at the P1 site and phenylalanine at the P1’ site exhibits relatively high inhibitory efficacy and 
reduced relative resistance against MDR769 [152]. We have designed and synthesized a LPV analog 
(Leu-LPV), containing a leucine-phenylalanine type substitution at the P1’ site. Our results suggest that 
both wild-type PR and the multidrug resistant (MDR) 769 protease variant are preferentially inhibited by 
the non identical ligands, and particularly by those ligands containing an isobutyl group in the P1 site and 
a phenylalanine group in the P1’ position inducing asymmetry in the MDR HIV-1 PR resulting in reduced 
relative resistance.  
3.2. Results 
3.2.1 Leucine lopinavir reduces the relative resistance against the MDR HIV-1 
Protease 769  
The half maximal inhibitory concentration (IC50) of Leu-LPV with an isobutyl P1 group was 
determined and listed in Table 3.1. The IC50 values of the synthesized original LPV control the CA/p2 F-
r-L and the CA/p2 F-r-F were also measured. Leu-LPV achieved 50% inhibition of the WT HIV-1 
protease and MDR 769 at the concentration of 2.1±0.1 nM and 6.8±0.4 nM, respectively. The inhibition 
efficacy of Leu-LPV was higher than the LPV control synthesized in parallel which exhibited the IC50 
values of 2.5±0.5 nM and 16±0.6 nM for the WT HIV-1 protease and MDR 769, respectively. 
Furthermore, Leu-LPV decreased the relative drug resistance from 6.4 to 3.2. The CA/p2 F-r-L still 
showed the lowest IC50 value (4.4±0.2 nM) inhibiting the MDR HIV-1 protease as well as having the 
lowest relative resistance (1.7 fold). 
 
 
 
 
 
  
 
Table 3.1. Half-maximal inhibitory concentration (IC50) 
Compounds (nM) 
HIV-1 protease Relative 
resistance NL4-3  MDR 769 
leucine lopinavir  2.1±0.1 6.8±0.4 3.2 
lopinavir control* 2.5±0.5 16±0.6 6.4 
CA/p2 L-r-F 2.6±0.4 4.4±0.2 1.7 
CA/p2 F-r-F 30.7 142 4.6 
*The lopinavir control was synthesized in parallel using the same procedures and equipments. The only 
different reagent is benzyl chloride instead of 1-chloro-2-methyl propane. 
3.2.2 Non-identical P1 and P1’ groups induce asymmetric 80’s loop conformations 
of the MDR HIV-1 protease 769 
The combination of isobutyl and benzyl group as P1 and P1' sites could induce an asymmetric 
movement of the mobile 80’s loops of the HIV-1 protease. In Figure 4A and 4B, the MDR 769 82T-(F-r-
L) complex crystal structure was superimposed to the WT HIV-1 protease-LPV complex crystal structure 
(PDB 2Q5K) [153] .  
Compared to the protease 80’s loops interacting with the identical P1 and P1’ benzyl groups of LPV, 
the P1 leucine of CA/p2 F-r-L peptide brought the protease 80s loop closer to the P1 group (Figure A) 
while the phenylalanine P1’ group of the CA/p2 F-r-L peptide induced a similar loop conformation as that 
of the LPV complex (Figure 4B) despite the similar binding mode of the reduced peptides (Figure 3.3). 
The non-identical conformations of protease 80s loops have also been observed in the MDR 769 82T-
darunavir complex due to the non-identical P1 (benzyl) and P1’ (isobutyl) groups of darunavir [69]. The 
identical CA/p2 F-r-F binds to the MDR HIV PR in a similar manner as LPV with the WT HIV-1 
protease and no such 80’s loop movement is observed.  
 
  
 
 
 
Figure 3.2. 80’s loop analysis of crystal structures. The lopinavir-WT complex is shown in light gray 
with lopinavir and proline 81 in stick model. The MDR complex structures with CA/p2 L-r-F (A) and 
CA/p2 F-r-F (B) shown in dark gray. These structures were superimposed based on the Cα positions of 
the HIV-1 protease.  
 
 
 
 
  
 
Table 3.2. Crystallographic statistics of CA/p2-MDR 769 complexes. 
 
Figure 3.3. Electron density 2|Fo|-|Fc| omit map of reduced peptide ligands; the asymmetric CA/p2 L-r-F 
(A) and the symmetric CA/p2 F-r-F (B) are shown in stick model with their corresponding electron 
density maps at a sigma level of 1.0. The peptide residues are labeled as P3 through P4’.  
aRmerge= Σhkl Σi |Ii (hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity of an observation and 
I(hkl) is the mean value for its unique reflection. 
bRwork =Σhkl ||Fo|−|Fc|| / Σhkl |Fo|, where Fo and Fc are the observed and calculated structure factor 
amplitudes. Rfree is calculated exactly as Rwork using a random 5% of the reflections omitted from 
refinement. 
3.2.3. Simulation analysis of leucine lopinavir binding to the MDR HIV-1 protease 
revealed movement of the 80’s loop towards the active site 
 The LPV and isobutyl P1 Leu-LPV in complex with MDR 769 were modeled and simulated for 10 
ns. The average conformations of the last 200 ps simulation were analyzed for both the LPV and Leu-
LPV complexes. In the average conformation of the MDR 769-LeuLPV complex simulation, the 
  
 
asymmetric conformation of protease 80’s loops was observed as well. One 80’s loop of the MDR HIV-1 
protease 769 moved closer to the isobutyl P1 group of the Leu-LPV (Figure 3.4). The interaction energy 
calculated between the inhibitor and protease is listed in table 3.3. The calculated interaction energy 
suggested that the Leu-LPV interacted with MDR 769 stronger (-99.47 kcal/mol) than LPV did (-92.39 
kcal/mol). The interaction energy was increased in both electrostatic interactions and van der Waals 
interactions.  
 
Figure 3.4. MD simulation of lopinavir and leucine lopinavir complex. The average coordinates of the 
last 200 ps of MD simulation of the MDR 769 in complex with lopinavir (light gray) and leucine 
lopinavir (dark gray) were superimposed based on the Cα positions of the HIV-1 protease.  
 
Table 3.3.  Interaction energy of lopinavir and leucine lopinavir in MDR 769 HIV-1 protease. The 
interaction energies from the 10ns simulation of LPV and Leu-LPV with MDR protease are given in 
kcal/mol. 
 
 
  
 
3.3. Discussion 
The drug-resistant mutations may increase the flexibility of HIV-1 protease and therefore alter the 
active site conformation to be unfavorable for drug binding. The 80’s loop is a mutation hot spot of HIV-
1 protease; as it directly interacts with the P1 and P1’ group of substrates or drugs. The 
V82A/C/F/I/L/M/S/T mutations on the loop have been identified [67, 154]. Both structural analyses and 
enzymatic results indicate that a smaller P1 or P1’ group, such as leucine, brings the 80s loop closer to the 
ligand and increases binding affinity. An isobutyl group at the P1 or P1’ position suggests a promising 
role to aid in overcoming drug-resistance in the expanded active site cavity.  
The lopinavir analog, LeuLPV does not reach the inhibitory potency of CA/p2 F-r-L against the 
MDR 769 protease. The potency of CA/p2 F-r-L may be influenced by the glutamic acid at P2’. Studies 
have shown that the binding efficacy of reduced peptides with a glutamic acid in the P2’ position are pH-
sensitive [155]. The electrostatic interactions of the CA/p2 F-r-L reduced peptide are superior to the 
hydrophobic Leu-LPV, which explains the relatively lower potency of Leu-LPV compared to the CA/p2 
F-r-L reduced peptide. 
LeuLPV with an isobutyl group at the P1 position may serve as an HIV-1 protease inhibitor against 
MDR proteases, especially MDR HIV-1 proteases containing mutations on the 80s loops. Currently, 
genotypic assays are recommended to assess resistance in the adult and adolescent guidelines of 
antiretroviral treatment [151]. Benefiting from protease gene sequences of patience isolates, the choice of 
optimal regimen could be decided based on the types of drug-resistance mutations. Therefore, there is a 
demand for developing modified protease inhibitors against various groups of HIV-1 protease variants.  
3.4. Author’s Contribution 
 The author conducted the protein expression of MDR 769 HIV-1 protease D25N A82T, the 
crystallization screening, setup, solved the crystal structures, data analysis and interpreted the data. The 
diffraction data collection and initial data processing were conducted by Dr. Joseph S. Brunzelle 
  
 
from the Department of Molecular Pharmacology and Biological Chemistry, Feinberg School of 
Medicine, Northwestern University, Chicago, IL. 
  
 
Chapter 4: Structure based design of modified lopinavir analogs 
targeting the multi-drug resistant HIV-1 protease 
4.1. Introduction 
One of the main challenges in treating and curing HIV is dealing with the development of drug 
resistance. HIV-1 protease is an aspartyl protease responsible for cleaving the gag/pol polyprotein 
resulting in mature virus particles. Inhibiting the protease leads to viral suppression as indicated by a 
reduced viral load. Previous work in our lab has shown that drug resistance mutations lead to 1) an 
expanded active site cavity, 2) an enlarged substrate envelope, 3) alternative 80’s loop conformations and 
4) altered binding modes of approved protease inhibitors compared to the WT [31-33, 69]. These factors 
contribute to reduced binding affinity and reduced inhibitory efficacy of the FDA approved inhibitors. 
Therefore designing inhibitors to combat the drug resistance problem is essential to next generation 
therapies. 
 
Figure 4.1. Chemical structure of the FDA approved protease inhibitor lopinavir.  
 
This chapter further explores modifications to the FDA approved HIV-1 protease inhibitor 
lopinavir (Figure 4.1) to enhance efficacy against two drug resistant variants, the clinical isolate MDR 
769 and the darunavir resistant I54V mutation. To test the non-identical P1/P1’ hypothesis (Chapter 3), 
we designed additional modifications to the P1 and P1’ positions in silico. These modifications were 
designed to explore the role of size diversity and identity of P1 and P1’ in binding to drug resistant 
  
 
protease variants. Compounds 1-18 contain modifications at only P1, while compounds 19-36 contain 
modifications at both P1 and P1’ resulting in an identical and non-identical series (Table 4.1). 
Table 4.1. Modifications made to the P1 or P1’ positions of lopinavir 
 
The modified lopinavir analogs were submitted for automated docking with the online software 
SwissDock. Docking with SwissDock is a computer based method to predict binding affinity and binding 
modes using the CHARMM forcefield (Chapter 2.6) [136, 137]. This program has been proven to be 70% 
accurate within 2Å of the crystal structure. Using the SwissDock output we performed additional analysis 
in UCSF Chimera, a molecular graphics program, to visually inspect and identify the top 7 compounds in 
our series[145]. Three criteria were used to make these selections. We choose the compounds that had 1) 
the highest predicted binding affinity in kcal/mol, 2) maintained key contacts such as coordination of the 
hydroxyl group to the aspartic acid residues in the active site, D25 and D25’, 3) were consistent in criteria 
1 and 2 across three different protease targets; WT, MDR 769, and darunavir resistant I54V.  The 
  
 
SwissDock output for the lopinavir control was validated using the crystal structures 3D20, 3SPK, and 
2O4S. 
Further analysis the top three scoring analogs and the lopinavir control, using 10 ns all-atom 
molecular dynamics simulations with scalable molecular dynamics with NAMD, confirmed p-
fluorobenzyl lopinavir (compound 20) as the lead compound. Structure-activity relationships of these 
analogs suggest two important strategies for rational drug design of protease inhibitors: (1) the presence 
of fluorinated P1 or P1’ groups enhance the binding affinities in both wild-type and MDR PR variants and 
(2) fluorinated compounds contribute to stabilizing the protein backbone by increasing hydrophobic 
contacts between the protease and the inhibitor. These factors may increase overall efficacy against MDR 
protease variants. 
4.2. Results 
4.2.1. Fluorinated lopinavir has the highest predicted binding affinity against drug 
resistant HIV-1 protease. 
 Compound 20 has the highest average binding affinity with the lowest standard deviation across 
the three different isolates. The predicted binding affinities of the top scoring compounds are shown in 
Figure 4.2 in order of their docking score. The top 3 compounds have similar binding affinities in the WT 
protease and in the single mutant containing the I54V mutation. In addition these compounds display 
comparable binding affinities as lopinavir. In MDR 769 however the performance of the compounds is 
reduced where the top four compounds have a higher binding affinity than LPV.   
  
 
 
Figure 4.2 SwissDock binding affinities of the lopinavir analogs 
4.2.2. P1/P1’ fluorinated lopinavir stabilizes the HIV-1 protease 
The RMSD over the 10 ns trajectory (figure 4.3 A) is used as a measure of flexibility and protein 
stability during an MD simulation. Lower RMSD corresponds to increased rigidity and therefore 
stabilization of the protease. Therefore inhibitors that lower the RMSD and have an enhanced binding 
affinity are more favorable. The average RMSD of the top 3 modifications as well as the lopinavir control 
in complex with the WT, MDR 769, and I54V protease variants is shown in figure 4.3, B. The compound 
that performs similarly in WT and the drug resistant variants would then have a higher barrier of 
resistance. This means that if a patient were to be taking compound 20 for example and managed to 
develop the mutations present in MDR 769, they would not have to change their treatment regimen.  
  
 
 
 
Figure 4.3 Root mean square deviation (RMSD) of Cα backbone atoms for the HIV-1 
Protease-ligand complexes. A. Average RMSD of all backbone atoms over the 10 ns trajectory. The 
PDB codes of the protease targets are shown in the figure legend. B Average RMSD for of each HIV-1 
protease isolate. The arrows indicate the p-fluoro 
 
  
 
4.2.3. P1/P1’ fluorinated lopinavir increases non bonded interactions with HIV-1 
protease. 
The final frame of the molecular dynamics simulations was submitted to LigPlot+ to identify non 
bonded interactions between the ligand and the target protein. The final frame of the MD was used 
because in this method the conformational sampling later in the trajectory is likely to be more 
energetically favorable.  Interestingly, the p-fluorinated lopinavir complexes not only increase the number 
of contacts but also the changes the residues involved in these contacts as seen in the LigPlot+ diagram 
(Figure 4.4). 
 
Figure 4.4. p-fluorinated-LPV interacts with alternative HIV-1 protease residues.  
Left WT (2O4S), middle MDR 769 (3SPK) and right I54V (3D20). 
 
Compared to LPV, compound 20 has increased contacts with all 3 protease variants. The specific 
interactions that are gained and lost as compared to the LPV complexes are shown in Table 4.2. The 
different protease variants cause an alteration in the binding mode of compound 20 and those binding 
modes are shown here. An important feature of compound 20 is that it is flexible enough to accommodate 
the altered binding pockets of the protease variants and the fluorine groups’ increase and alter the 
hydrophobic contacts with the protease regardless of the differences in the binding pockets caused by the 
drug resistant mutations. 
  
 
Table 4.2 Non bonded interactions identified by LigPlot+ analysis 
 LPV P1/P1’ Fluoro 
 Hydrophobic 
Contacts 
Hydrogen Bonds Hydrophobic 
Contacts 
Hydrogen 
Bonds 
2O4S 
(22:23) 
A28  A28’ 
G27 
G48  G48’ 
G49  G49’ 
I47    I47’ 
I50    I50’ 
I84 
P29 
P30 
P81 
V32  V32’ 
V82 
 
D25  D25’ 
D29 
G27 
A28  A28’ 
D29 
D30  D30’ 
G27 
G48 
G49  G49’ 
I47    I47’ 
I50 
I84    I84’ 
L23 
R8 
V32   V32’ 
V82   V82’ 
D25   D25’ 
G27 
3SPK 
(16:21) 
A28 
D29 
D30 
G27 
G48 
G49 
I50    I50’ 
L23 
P81 
R8 
V32 
V84 
G49 
N25 
P25 
 
A28   A28’ 
D25 
D29 
D30   D30’ 
G27 
G48   G48’ 
G49   G49’ 
I47 
I50     I50’ 
L23 
R8 
T82 
V32 
V84 
D29 
N25 
 
3D20 
(21:23) 
A28    A28’ 
D25 
D29   D29’ 
D30 
V32   V32’ 
G27   G27’ 
G48   G48’ 
G49 
I50 
I84 
L23    L23’ 
R8      R8’ 
 
D25’ 
I50’ 
A28    A28’ 
D25 
D29 
D30’ 
G27    G27’ 
G49    G49’ 
I47      I47’ 
I50 
I84 
L23 
P81 
V32    V32’ 
V82 
D25’ 
D30 
I50 
R8        R8’ 
 
 
 
  
 
Table 4.3 Non bonded interactions gained and lost in the HIV-1 protease-(20) complexes as compared to 
the HIV-1 protease-lopinavir complexes.  
 
*denotes hydrogen bonds  
 
4.3. Discussion 
 Treating patients who have acquired drug resistance remains a major challenge in HIV-1 therapy 
and represents a major barrier towards viral eradication. While eradication is a lofty goal we can certainly 
begin with developing inhibitors to combat resistance using structural approaches. In this chapter, we 
have designed a series of lopinavir analogs with modifications at either P1 or both P1 and P1’ positions to 
explore the role of size diversity in at these loci.  
 Our results suggest that the presence of fluorinated  P1 or P1’ groups, particularly p-fluorobenzyl 
at P1 and P1’, produces greater binding affinity to multi-drug resistant HIV-1 protease variants. 
Substitution of the benzene ring hydrogen at the para position facilitates an increase in the number of 
contacts between the ligand and the protease target. In addition to increasing the total number of contacts 
an alternative binding pocket is formed in each of the protease targets (Figure 4.5). This suggests that the 
ability of the ligand to adapt to the conformation of the active site while maintaining or increasing 
contacts with the protease is a major contributor in reducing fluctuations in binding affinity across 
multiple protease variants.  
 Analysis of MD simulation data further suggests that these groups play a role in stabilizing the 
protein backbone and therefore may increase overall efficacy against MDR protease variants. Compound 
  
 
20 is capable of significantly reducing the RMSD in the protease variants as well as the wild-type 
compared to the lopinavir control. Stabilizing the protease backbone by increasing the number of contacts 
between the ligand and the target protein may be an effective strategy to combat multi-drug resistance 
amongst protease inhibitors.  
  
 
 
Figure 4.5 Alternative binding pocket induced by p-fluorinated lopinavir in each HIV-1 protease variant  
A. Wild type, B. MDR 769, C. I54V 
  
 
4.4 Author’s contribution 
The author developed the experimental design, designed the lopinavir analogs, and interpreted the 
data from the MD simulations. Bradley Keusch performed the docking, the molecular dynamics 
simulations and the MD data analysis. 
  
 
Chapter 5: Characterization of multi-drug resistant HIV-1 protease 
isolates 
5.1. Introduction 
 In the treatment of HIV/AIDS, the HIV-1 protease inhibitors (PIs) represent a key class of drugs 
[156]. PIs have a higher barrier of resistance relative to other classes of inhibitors [157, 158] in which 
multiple protease (PR) mutations are needed for developing resistance [157-159]. In spite of an intensive 
and concerted effort, no straightforward solution exists to the HIV-1 PR drug resistance challenge. The 
HIV-1 PR is a small aspartyl protease consisting of 99 amino acid residues. It is significantly smaller than 
mammalian aspartyl proteases  and has a dimeric structure of two identical monomers [160, 161]. Two 
aspartyl residues, one from each monomer, are responsible for catalyzing proteolyses of the HIV-1 
polyproteins. The HIV-1 PR active site is located in a cleft that binds the viral polyprotein in which large 
conformational changes occur upon substrate or inhibitor binding.  
 While the design of HIV-1 PIs has been a success resulting in the PIs ATV, DRV, FPV, IDV, 
NFV, LPV, SQV, and TPV, the problem of HIV-1 PR drug resistance remains unsolved. Shown in figure 
1 the HIV-1 protease of a patient who currently receives ART with a combination of drugs other than PIs 
since resistance testing of the patient’s HIV-1 has indicated resistance to all licensed PIs. Recently, the 
patient has developed resistance to her current ART drugs, leaving this patient with challenging future 
treatment options. In this chapter, a set of Detroit patient isolates has been selected, including this 
patient’s drug resistant HIV-1 PR. 
 
  
 
 
Figure 5.1. HIV-1 protease resistance mutations from a Michigan patient isolate selected for our studies. 
The resistance mutations are shown by the white side chains. The theoretical model of the complex (PR: 
rainbow diagram,  LPV: space filling model) is based on our crystal structure (1RV7) of another MDR 
HIV-1 protease bound to LPV  [162]. 
 
 According to the UNAIDS, 70% of treatment failures are caused by drug resistant mutations. This 
highlights the importance of understanding the molecular mechanisms by which HIV-1 drug targets are 
able to evade inhibition by potent inhibitors. The Detroit isolates differ from isolates previously studied in 
our group in that these contain the major drug resistance mutations I47V, I50V, I54M, L76V, V82I/F, and 
I84F not present in the previous cohort. The Detroit isolates also contain previously identified non-
polymorphic accessory mutations L10V/G, V11I, K20T/R, L33F/I/M, K43T, F53L, A71L, T74P, and 
L89V.  Interestingly, all of the Detroit isolates contain the previously unidentified I13V mutation and 
L33F. The Detroit isolates represent an interesting cluster to study the effect of both major and accessory 
mutations on protease inhibitor resistance.  
Sequence comparisons between the Detroit Isolates highlight the differences as well as the 
common mutations present in each isolate (figure 5.2). All three isolates contain the 33F, 46I, and 84V 
major drug resistance mutations. The structural mechanisms leading to differences in predicted 
vircoTYPE scores between these isolates is unclear from the virtual phenotype predictions alone. 
Molecular dynamics simulations of the Detroit isolates were performed using NAMD. The results of 
  
 
these simulations show that (1) V32I and I47V play a structural role in tethering the protease flaps to the 
active site, (2) I54M and L90M may be responsible for asymmetric movement of the protease flaps, and 
(3) Alternative hydrogen bonding networks with ligands are important factors contributing to the 
molecular mechanisms of protease inhibitor resistance.  
 
Figure 5.2. Mutations present in the Detroit Isolates. A. Major HIV-1 protease drug resistance mutations,  
B. Minor/accessory mutations. 
 
5.2. Results 
5.2.1 The Detroit isolates display multi-drug resistant virtual phenotype 
The protease sequences of the Detroit Isolates were submitted for virtual phenotype predictions 
with vircoTYPE. This software uses an input sequence, along with known information regarding 
resistance mutations to calculate quantitative levels of phenotypic susceptibility to the entire class of 
protease inhibitors. Clinicians use this information as a guide when prescribing personalized therapy for 
their HIV infected patients. The vircoTYPE predictions of the Detroit Isolates suggest that DetMDR1 is 
completely resistant to all 9 protease inhibitors currently on the market (Table 1). DetMDR2 may be 
susceptible to DRV with reduced susceptibility to IDV, SQV, LPV, and ATV. DetMDR3 however may 
still be susceptible to saquinavir and tipranavir with reduced susceptibility to lopinavir, atazanavir and 
indinavir. In addition, we performed the same analysis using the a rule based genotypic resistance 
algorithm provided by the Stanford Database and the virtual phenotypes align nicely in that DetMDR1 is 
  
 
resistant to everything, DetMDR2 displays low level resistance to darunavir, and DetMDR3 displays low 
level resistance to tipranavir (Table 5.1).  
Table 5.1. Virtual phenotype predictions of the Detroit Isolates with VircoType suggest multidrug 
resistant phenotype. Red: Minimal Response; Orange: Reduced Response; Green: Maximal Response; 
X/r = ritonavir boosted 
 
 
Table 5.2. Predicted phenotypes of the Detroit isolates from the Stanford Database rule based algorithm 
 
5.2.2 Mutations in the Detroit isolates reveal alternative protein dynamics 
Molecular dynamics simulations (Chapter 2.5) were performed for 40 ns with the Detroit Isolates. 
Root mean squared deviation (RMSD) of the PR backbone show increased fluctuation of all 3 isolates 
compared to the wild-type protease (Figure 3). DetMDR1 showed a jump in flexibility as while 
DetMDR2 shows are sharp increase in RMSD and sustained deviation for the rest of the trajectory. 
DetMDR3 displays short bursts of increased flexibility but no sustained changes in RMSD. This data 
suggest a large conformational change in isolates 1 and 2 but not in DetMDR3 or the WT.  
  
 
 
Figure 5.3. Root mean square deviation (RMSD) of Cα positions of the uncomplexed HIV-1 
protease isolates. Wild-type is shown in green, DetMDR1 in pink, DetMDR2 in blue and DetMDR3 in 
cyan. 
 
 Analysis of the average RMSD for each residue in the HIV-1 PR simulations compared to the 
WT highlight the differences in flexibility between these 2 and especially show the increased flexibility of 
certain regions of the PR. Specifically, the jump in average backbone RMSD of DetMDR1 is caused by 
asymmetric fluctuation of chain B in the flap regions of the PR corresponding to residues 45-55. 
Interestingly, the same region of DetMDR2 shows high flexibility variations compared to the WT 
however in DetMDR1 this sustained increased RMSD is not restricted to one chain rather the flap regions 
of DetMDR2 show significant deviation in both chains of the PR.  
  
 
5.2.3 Flap opening may play a role in drug resistance of the Detroit Isolates 
 Visual analysis of the trajectory shows that these increases in RMSD are due to opening of the 
flaps in DetMDR1 and DetMDR2. In DetMDR1 the flaps open and then close. In contrast, the flaps of 
DetMDR2 open and stay open for the remainder of the trajectory. The WT and DetMDR3 flaps do not 
open during these simulations. These differences in flap movement correspond to the presence or absence 
of particular mutations.  Interactions between the V32I and I47V mutations cause flap closure in HIV-1 
protease. I47V is present in both DetMDR1 and 2 where the flaps open, but not in DetMDR3 where the 
flaps do not open V32I is therefore a compensatory mutation which tethers the flaps to the active site 
through its vdW interactions with I47V (Figure 5.4). Similarly, the WT and DetMDR3 have V32 and I47 
at these loci and therefore the vdW interactions in the WT and DetMDR3 are maintained. The absence of 
V32I in DetMDR2 disrupts this interaction and therefore the flaps remain open in DetMDR2.  
 
 
Figure 5.4 Change in the van der Waals volume induced by the drug resistance mutations I47V and V32I. 
The left panel shows DetMDR1; the right panel shows DetMDR2.  
 
  
 
 
Figure 5.5 RMSD per residue of the uncomplexed HIV-1 protease isolates compared to WT reveal 
alternate flap dynamics of WT and Detroit MDRs: A. DetMDR1 B. DetMDR2 and C. DetMDR3. The 
flap regions corresponding to residues 47-54 show increase in RMSD on both protease chains in 
DetMDR2 and only on chain B of DetMDR1 
  
 
 
 I54M and L90M are associated with asymmetric movement in DetMDR1 corresponding to 
opening of the flaps. The RMSD of L90M on chain B is different than that of chain A. The asymmetric 
movement of the flaps indicated by the differences in RMSD at each residue show a difference in residues 
47-54 on chain B compared to chain A (Figure 5.5). Movement of the residues in this region is symmetric 
in DetMDR2 where the residue fluctuation per residue is conserved between both chains of the PR.  
5.2.4 Darunavir, atazanavir and lopinavir binding stabilize the HIV-1 protease flaps 
 The WT, DetMDR1, DetMDR2, and DetMDR3 in complex with DRV, ATV and LPV were 
submitted for 40 ns molecular dynamic simulations. The opening of the flaps observed in the 
uncomplexed simulations of DetMDR1 and DetMDR2 does not occur in the complex simulations. Drug 
binding maintains a closed flap conformation in DetMDR2 (Figure 5.6). 
 
 
Figure 5.6 Darunavir, atazanavir and lopinavir binding stabilize the HIV-1 protease flaps. The left panel 
showsn the average RMSD of DetMDR2 either alone (blue) or in complex with DRV (red) ATV (green) 
and LPV (purple). The RMSD per residue is shown in the right panel. 
 
In addition to the altered protein dynamics, there is a change in the hydrogen bonding interactions 
in the WT compared the MDR isolate complex (Table 5.2). DetMDR1 has 2.3%, 0.8% and 19.2% 
  
 
reduced hydrogen bond formation when complexed with darunavir, atazanavir and lopinavir respectively. 
Interestingly, DetMDR2 and DetMDR3 have increasing hydrogen bond formation when in complex with 
DRV and ATV; and a 21% and 36% decrease in hydrogen bond formation when in complex with 
lopinavir. The increase in hydrogen bonds is likely due to an alteration in the residues involved in an 
interaction with the protease thus, while changing the binding pocket may increase hydrogen bond 
formation; this also alters the conformation of the inhibitor. 
5.3. Discussion 
Three multi-drug resistant HIV-1 protease patient clinical isolates were selected from Wayne 
State University Infectious Disease Clinic failing antiviral treatment therapy using protease inhibitor 
based regimens. To explore the structural mechanisms resulting in treatment failure, we performed 40ns 
MD simulations on the Detroit MDR series. Our results indicate a novel structural role for the I47V, 
V32I, I54M and L90M resistance mutations. 
The V32I and I47V mutations play a structural role in tethering the flaps to the active site. 
Sequence analysis comparisons of the DetMDR protease isolates showed that DetMDR2 does not contain 
the V32I and I47V mutation combination rather it contains only the I47V mutation. Without the V32I 
mutation there is a loss in van der Waals contact volume between these two residues. Therefore, we 
postulate that I47V is responsible for flap opening however V32I is a compensatory mutation that may be 
responsible for tethering the flaps to the active site through its contacts with I47V. 
 I54M and L90M may be responsible for asymmetric movement of the protease flaps. This 
mutation combination is only present in DetMDR1 which is the only protease out of the series in which 
the flaps asymmetrically open and then close after 4 ns. The mechanism explaining asymmetric flap 
opening will be explored further in future characterization studies of the HIV-1 protease isolates.  
The role of these structural changes in drug resistance was investigated using molecular dynamics 
simulations with the Detroit isolates in complex with the protease inhibitors atazanavir, darunavir and 
lopinavir. These MD results suggest that drug resistance occurs through alternate hydrogen bonding 
  
 
interactions in each of the mutants. The alternate hydrogen bonding networks in addition to the flexibility 
of the flaps are stabilized with the protease inhibitors bound to the active site. This work highlights the 
importance of individualized treatment options specific to unique drug resistance variants identified in 
patients. 
 
Table 5.3 Hydrogen bonding network with darunavir, atazanavir, and lopinavir 
 LPV ATV DRV 
 Chain A* Chain B Chain A* Chain B Chain A* Chain B 
WT L23 
D25 
A28 
D29  
D30 
V32 
I47  
G49 
I50 
P81 
V82 
I84 
R8 
L23 
A28 
D30 
V32 
I48 
G49 
I50 
I54 
V56 
L76 
P81 
V82 
I84 
R8 
D25 
D29 
G48 
I50 
R8 
D29 
D30 
G48 
G49 
I50 
D25 
D29 
D30 
I50 
D30 
G49 
I50 
DetMDR1 D25 
A28 
D29 
D30 
I32 
V47 
G48 
G49 
I50 
T82 
 
A28 
D29 
D30 
V47 
G49 
I50 
M54 
L76 
P81 
T82 
V84 
R8 
D25 
D29 
D30 
I50 
T82 
R8 
D29 
D30 
G48 
G49 
I50 
T82 
D25 
D29 
D30 
I50 
D29 
D30 
I50 
T82 
DetMDR2 L23 
D25 
A28 
D29 
D30 
V32 
V47 
V49 
V81 
V82 
R8 
A28 
D29 
D30 
V32 
G49 
I50 
V82 
V84 
 
R8 
D25 
D29 
D30 
G48 
I50 
D29 
D30 
G49 
I50 
D29 
D30 
I50 
D30 
G49 
I50 
  
 
V84 
DetMDR3 D25 
D28 
D29 
D30 
V32 
I47 
G48 
G49 
I50 
P81 
I84 
R8 
A28 
D29 
D30 
I47 
G49 
I50 
P81 
V82 
I84 
 
R8 
D25 
D29 
G48 
I50 
R8 
D29 
D30 
G48 
G49 
I50 
D25 
D29 
D30 
I50 
D29 
D30 
G49 
I50 
 
5.4 Author’s contribution 
The author developed the experimental design and interpreted the analysis of the MD trajectories. 
Poorvi Chordia performed the MD simulations and the analysis of the MD. 
  
 
Chapter 6: Reduced flexibility of HIV-1 integrase as a mechanism of 
raltegravir resistance 
6.1. Introduction 
 HIV-1 integrase (IN) is a 32kDa protein encoded in the pol gene along with protease and reverse 
transcriptase. IN contains three structural domains; the N-terminal domain (NTD), catalytic core domain 
(CCD) and C-terminal domain (CTD). In order for HIV-1 viral replication to occur, the viral cDNA must 
be integrated into the host chromosome. This process, mediated by IN involves two chemical reactions. 
The first reaction is 3’ processing in which a specific dinucleotide sequence of the viral DNA 3’ ends are 
cleaved to generate reactive hydroxyl groups.  Next, the IN enzyme facilitates the transesterification 
reaction known as strand transfer, resulting in the successful integration of the viral DNA into the host 
chromosome [35].  
IN represents an interesting target for therapeutic intervention as it is essential to progression of 
HIV infection. IN requires divalent metal ions Mn
2+
 or Mg
2+
 for catalytic function [163]. Although 
reported crystal structures display only one metal ion (1BIU) in the active site coordinated by D64 and 
D116, crystal structures of the Avian Sarcoma Virus IN (1VSH) a structurally and functionally related 
enzyme show two metal ions in the active site. Aryl-2,4-diketobutanoic acids (DKAs) were identified as 
the first compounds to show successful inhibition of HIV IN likely via interactions with the required 
metal ions [164]. DKAs selectively bind to the IN donor substrate complex and inhibit strand transfer by 
competing with the target DNA [53]. IN strand transfer inhibitors are believed to bind to the IN-DNA 
complex post 3’ processing and sequester the Mg2+ ions coordinated by the catalytic triad residues D64, 
D116, and E152 [165]. Raltegravir (RAL) (Isentress, Merck & Co., Inc.), the first HIV-1 IN inhibitor to 
be approved by the FDA in 2007 for antiretroviral treatment, was optimized from the initial DKA 
pharmacophore and inhibits the strand transfer reaction in a mechanism that is not yet clearly defined 
[41].  
  
 
Several mutations leading to resistance to RAL have been observed both clinically and in vitro. 
The Stanford HIV Drug Resistance Database reports mutations at codons 92, 121, 140, 143, 148, and 155 
are associated with greater than 5-10 fold decreases in susceptibility to RAL (Fig.1). Primary mutations at 
143, 148 and 155 along with associated secondary mutations constitute the three main pathways leading 
to RAL resistance [166]. The Q148HRK/G140SA resistance pathway was observed most frequently in 
clinical trials and has been shown to be more fit than the RAL resistant single or double mutants in the 
presence of RAL suggesting that the G140 mutation may serve a compensatory role in rescuing IN 
activity [166, 167]. While the structural mechanisms explaining RAL resistance in the Y143 integrase 
mutants has been suggested to be through a loss of aromatic interactions in the 140’s loop, the precise 
mechanism by which the other mutations are RAL resistant remains unclear [168].   
Crystal structures of HIV-1 IN CCD have been previously reported, however none of these 
investigate structural changes, if any, that may occur as a result of these resistance mutations. The 
structure of the prototype foamy virus (PFV) intasome, a functionally related enzyme, complexed with 
DNA and RAL has provided some insight into IN structural properties and binding interactions, in the 
absence of available structural information involving the HIV-1 IN CCD and RAL [169]. Molecular 
dynamics (MD) simulations in combination with automated docking have been done to gain information 
regarding these resistance pathways and to identify possible binding modes of RAL in the CCD active 
site [170, 171].  
Using MD, the keto-enol groups of DKA IN inhibitors have been shown to be coordinated with 
magnesium ions in the active site as well as stabilize the flexible 140’s loop (138-149) through 
hydrophobic contacts [172]. Conformational changes in the 140’s loop have been implicated in binding 
interactions with the strand transfer IN inhibitors [173]. Here, we perform MD simulations concurrently 
on HIV-1 IN CCD and RAL to analyze protein and inhibitor flexibility as well as binding interactions 
within the protein inhibitor complex in the context of the 148/140 resistance pathway to investigate the 
structural changes occurring in the HIV-1 IN CCD as a result of these resistance mutations. The change in 
  
 
flexibility of the flaps of retroviral protease variants has suggested an important role in protein flexibility 
on inhibitor binding [174]. The mutant variants display an increased probability of the formation of a 
transient intraloop structure that causes increased rigidity and impairs the gating function of the catalytic 
140’s loop resulting in decreased RAL accessibility to the IN active site. In this paper, we explore the 
reduction in flexibility of HIV-1 IN as a mechanism for raltegravir resistance. 
6.2 Results  
6.2.1 Reduced flexibility of the HIV-1 integrase catalytic core domain caused by 
raltegravir induced drug resistant mutations 
The interaction between the CCD and the inhibitor RAL is mediated through two Mg
2+
 ions in the 
active site. These ions coordinate the carboxylate groups of the catalytic residues Asp 64, Asp 116, and 
Glu 152 such that the DDE motif interacts with the Mg
2+
 ions. The coplanar oxygen atoms on RAL also 
coordinate to the Mg
2+
 ions thereby inhibiting the movement and function of the catalytic residues. The 
coordination of the PFV structure shows monodentate interactions with Mg
2+
 for Asp116, and bidentate 
for Glu 152. Our simulations post equilibration suggests the possibility of bidentate for both Asp 116 and 
Glu 152. 
Figure 6.1a shows the average RMSD of the backbone atoms for each complex over the duration 
of the MD simulation calculated in reference to the starting structure for each complex. The initial 
increase in RMSD is due to the energy minimization and equilibration steps.  The average RMSD values 
for the wild-type, 148H, 148H/140S, 148R, 148R/140A complexes are 2.43 Å, 1.92 Å, 1.99 Å, 1.86 Å 
and 1.63 Å respectively. Mutations as residue 148 and 140 cause reduced flexibility with the most rigidity 
observed in the 148R/140A mutant.  
The residues with the highest RMSD values are shown in figure 6.1 (b-f). With the exception of 
the 148H mutant, the α6 helix at the C-terminal end of the CCD contains residues with high RMSD 
values (Fig 6.1b). The high RMSD residues in the 148H mutant are localized to the loop connecting helix 
α5 and α6. The catalytic residue Glu 152 is located on the N-terminal side of α4. The 148R and 
  
 
148R/140A mutants shown in figure 6.1e and 6.1f respectively have high RMSD residues in the hinge 
region between helix α4 and α5. This increased flexibility changes the shape of the active site by causing 
helix α4 to bend outward. The strain of this helix causes the side chain of Glu152 to move out of range for 
an ionic interaction coordinating the Mg
2+
 ion between Glu 152 and Asp 64. The chelation of the active 
site Mg
2+
 ions by raltegravir is required for inhibition of integrase strand transfer [165].  
 
 
Fig. 6.1 The HIV-1 integrase mutants are less flexible than the wild type. RMSD of backbone 
atoms for IN during 10 ns MD simulation. High RMSD residues are shown in black, catalytic residues in 
blue and RAL resistance mutations shown in red. a RMSD in Angstroms per frame over the 10 ns 
  
 
trajectory. Average RMSD values are shown in parenthesis. b 148H. c 148H/140S. d WT. e 148R. f 
148R/140S. 
 
 
Figure 6.2. Changes in the 140’s intraloop region as indicated by variation in φ, ψ angles in 
the codon 140 and 148 mutants of the HIV-1 integrase.   Ramachandran plot of φ, ψ angles in the 
140’s loop over the 10 ns trajectory. 
 
6.2.2 Transient helix formation and variability in the catalytic 140’s loop 
The 140’s loop (139-150) transiently changes from a random coil to an intraloop helix throughout 
the 10 ns simulation (Table 6.1). In the WT, F139 has average φ, ψ angles of -119.6° and -170.9° 
respectively corresponding to a β sheet conformation; however values for these angles do occupy the 
right-handed helix range at times during the trajectory (Fig. 6.2). The span of calculated φ, ψ angles is 
similar to that of WT for the 148H and 148R single mutants however the average φ, ψ angles for residue 
F139 in 148H are -95.5° and -74.6° respectively, corresponding to a movement towards a more alpha 
helical structure. G140 residue (WT, 148H, and 148R) experiences changes in its ψ angle spanning values 
  
 
for β sheets with few frames drifting towards a left-handed helix. In contrast, the double mutants 
containing G140S and G140A substitutions change values for the φ angle resulting in averages 
corresponding to α helix and β sheet respectively. While the single mutants also contain a glycine at 
residue 140 these mutants experience changes in both φ and ψ angles throughout the trajectory. 
The φ and ψ angles of residues 141-145 are relatively consistent in each complex; while most of 
the time this loop is in the form of a random coil, a transient helix is formed in this region as well (Table 
6.1. The formation of a 3 residue helix in this loop is a naturally occurring secondary structure element as 
observed in the wild-type (Fig 6.3c). Sample frames were taken post energy minimization and at 1 ns 
intervals. In the WT a helix is formed in the 140’s loop consisting of residues 144-146, 141-143, or 141-
146 during the 10 ns sampling. When a helix forms in this loop it likely inhibits binding of RAL to the IN 
CCD. The 140’s loop helix forms in the 148R (fig. 6.3d) mutant. Similar to the wild-type, the 144-146 
and the 141-146 helix forms. The Q148R mutation induces the formation of a new helix consisting of 
residues 141-144 and is the only helix formed in the 148R/140A mutant (fig. 6.3e). The 141-144 helix is 
likely an extension of the 141-143 helix observed in the WT ensemble.   
Table 6.1 Intraloop helix formation in the catalytic 140’s loop. Composition of the intraloop helices 
observed during the simulation are indicated with the letter Y.  
 
 
The 148H mutant (Fig.6.3a) forms a helix with residues 141-144, 144-146, 144-147, 141-146, 
and 143-147. In the 148H/140S mutant (Fig 6.3b), the 144-147 helix formed with the 148H mutation 
alone was formed. The 141-146 and the 144-146 helix observed in the WT also occurred in the 
  
 
148H/140S double mutant. A fourth helix was formed consisting of residues 141-147. The 144-147 helix 
is an extension of the 144-146 helix observed in the WT.  In each of the double mutants the most 
frequently formed helix represents a shift from a 3-residue helix in the WT to a 4-residue helix in the 
mutant suggesting that in addition to the frequency of helix formation, the length of the helix is also a 
contributing factor to RAL resistance. The single mutation of Q148H/R induces the formation of a new 4 
residue helix that is advantageous against RAL. The secondary mutation, G140S/A, ensures the formation 
of an extended helix.  
 
Figure 6.3. Extension of the HIV-1 integrase 140’s intraloop helix for the codon 140 and 148 
mutants. Structure ensemble composed of frames post energy minimization and 1ns intervals 
demonstrate transient structural changes occurring during the 10 ns MD simulation. The arrows indicate 
the position of the 140’s loop helix. a 148H b 148H/140S. c WT. d 148R. e 148R/140A 
 
Variations in the φ, ψ angles begin again at residue 146 which is the end of the observed helices 
formed in WT IN. Q146 has similar φ ψ angles for the WT, 148H, 148H/140S, and 148R. The 148R 
mutant however has an average φ angle of 172.3° corresponding to β-sheet structure and none of the 
  
 
frames during the 10 ns have φ, ψ angles corresponding to α-helix throughout the 10ns simulation. In the 
presence of the 148H/S mutation S147 is primarily restricted to angles that form helical secondary 
structure however in the WT this residue can span the entire range of allowed φ angles. Important in 
catalytic function, this transient intraloop structure is likely responsible for impaired dynamics of the 
140’s loop gating function in these mutants [175].  
 Residues 120 to 122 compose a transient helix, α2 that is observed as a random coil in some 
crystal structures of the IN CCD and an α-helix in others. In the ensemble presented here, α2 is a random 
coil in the WT ensemble, while the mutants 148R, 148R/140A, 148H and the 148H/140S double mutant 
remains structured as a helix. F121Y , located in this region, is a resistance mutation that has been 
observed in patients that leads to cross resistance in clinically tested IN inhibitors including RAL [176]. 
This mutation does not occur concurrently with mutations at 140 and 148 however the presence or 
absence of α2 may play an important role in resistance. 
  In the 148H/140S mutant, β5; which consists of residues 136-139 is missing in the structures at 
post-equilibrium and 10 ns resulting in an extension of the 140s loop by 6 residues. Helix α2 is also 
missing in these structures. E138K is a resistance mutation that leads to a 2 fold decrease in susceptibility 
to RAL and other IN inhibitors compared to the WT [176]. 
6.3 Discussion 
 In this study, 10 ns MD simulations were carried out to investigate the structural changes 
occurring in the HIV IN CCD as a consequence of the RAL resistance mutations Q148H/R and G140S/A. 
The RMSD data show that the mutants have reduced flexibility. Detailed analysis of the φ, ψ angles using 
the Ramachandran plots in the 140’s loop revealed alternative positions of the transiently formed helix in 
this region. The transient loss of secondary structure in α2 and β5 suggest a common mechanism for 
resistance to RAL as 2 of the 3 major pathways to resistance involve residues located in these regions 
with alternating secondary structure. The ability of this loop to experience these conformational changes 
in our modeled system supports the requirement for DNA in order for RAL to effectively inhibit strand 
  
 
transfer. The increased rigidity of the 140’s loop may impair its gating ability contributing to both a 
decrease in normal catalytic function as well as a resistance mechanism to RAL [91]. This loss of protein 
flexibility may serve to decrease the residence time observed in the RAL resistance mutants compared to 
wild type [52]. These secondary structure elements are not only required for function but play an 
important role in the development of HIV IN resistance to RAL and other integrase strand transfer 
inhibitors. 
6.4 Author’s contribution 
 The author performed the system setup, energy minimization and molecular dynamics, and data 
analysis. 
  
 
Chapter 7: Structure based modeling of the HIV-1 intasome 
7.1 Introduction 
 HIV-1 integrase is a 32kDa protein with 288 amino acid residues comprising three distinct 
domains; the N-terminal domain (NTD), catalytic core domain (CCD) and the C-terminal domain (CTD). 
To date, structures of the NTD, CTD, CCD, NTD with CCD and CCD with CTD have been deposited 
into the Protein Data Bank; however crystallization of the full length HIV-1 integrase remains elusive 
[177-180]. Structural information on the full length HIV-1 integrase is necessary to more fully understand 
host-viral interactions, understand antiviral resistance as well as aid in the development of a platform for 
structure based drug design. 
 The NTD contains four helices and tetrahedally coordinates His12, His16, Cys40 and Cys43 to a 
zinc cation as shown in figure 7.1 [181]. This domain is involved in multimerization as well as facilitating 
the interaction between HIV-1 integrase and the cellular host factor lens epithelium-derived growth factor 
(LEDGF) [182]. LEDGF-IN binding primarily determines the efficiency and specificity of HIV-1 
integration into actively transcribed regions of the host chromosomal DNA [183, 184].  
 
Figure 7.1 The N-terminal domain of HIV-1 integrase is tetrahedrally coordinated to a Zinc cation in an 
HHCC motif. Zn
2+ 
is shown as a black sphere, the dashed lines represent coordination to the HHCC motif. 
 
  
 
 The CCD is responsible for chelation of divalent metal ions magnesium and/or manganese in the 
active site, is involved in DNA binding and has a highly conserved D,DX35E motif consisting of Asp64, 
Asp116, and Glu152 serving as the catalytic triad [185]. The catalytic core domain performs 3’processing 
and strand transfer via in-line bimolecular nucleophilic substitution (SN2) reaction [186]. In addition to 
catalytic function the CCD contains residues 186-188, involved in multimerization and may be important 
for cellular localization [187].  
 The CTD is involved in nonspecific DNA binding. It contains an 18-residue C-terminal tail which 
has not been solved structurally but may play an important role in mediating the interaction between 
integrase and reverse transcriptase; as mutant integrase virions display a reverse transcription defect 
[188].  The CTD has also been reported to interact with several host integration factors including importin 
alpha3, transportin 3 and transportin-SR2 to assist in reverse transcription, nuclear import, or integration 
[189-192].  
 
Figure 7.2 structural similarities between HIV-1 integrase and PFV integrase catalytic core domains. 
Superposition of the catalytic domain of the PFV intasome (cyan) and HIV-1 CCD (green). Magnesium 
ions (magenta) from the starting HIV-1 crystal structure 1BL3. Catalytic residues are shown in stick 
model. 
  
 
 The full length structure of the prototype foamy virus (PFV) integrase, a structurally related 
retrovirus, was solved in the presence of its cognate DNA, divalent metal ions, and a number of strand 
transfer inhibitors, including RAL, EVG and DTG [169]. Figure 7.2 shows the superposition the HIV-1 
catalytic core domain with the PFV structure. These structures have provided insights into the mechanism 
of action of integrase inhibitors by serving as a model for HIV-1 intasome [193]. Using the PFV structure 
we have developed a model of the full length HIV-1 intasome shown in figure 7.3. Here, we perform 15 
ns molecular dynamics simulations of the full length HIV-1 integrase in complex with the viral DNA 
ends and raltegravir to investigate the structural interactions in this ternary complex leading to reduced 
efficacy of raltegravir against resistant HIV-1 integrase mutants.  
 
 
Figure 7.3 Full length HIV-1 integrase modeled from PFV integrase. (A) Prototype foamy virus integrase 
from PDB 3OYA with the CCD shown in green, CTD shown in blue, NTD shown in red and NED shown 
in dark grey. (B) Full length model of HIV-1 integrase with same color scheme for each domain. The 
HIV-1 IN model was built from the CCD structure (1BL3), NTD and CCD structure 1K6Y, and the CTD 
and CCD structure (1EX4). 
 
  
 
7.2 Results 
7.2.1 Reduced flexibility of raltegravir resistant Q148H, G140S and N155H, E92Q 
double mutants 
 The full length model of HIV-1 integrase was built by combining the CCD structure (1BL3), 
NTD and CCD structure 1K6Y, and the CTD and CCD structure (1EX4). Therefore, initial increase in 
RMSD (Figure 7.4 A) is due to energy minimization of the modeled HIV-1 integrase. The average RMSD 
of backbone atoms for the entire 15 ns trajectory was 6.22 Å, 4.89 Å and 4.61 Å in the WT, HS and HQ 
simulations respectively (Figure 7.4 B).  Consistent with the findings from modeling the CCD with RAL 
(Chapter 6), the double mutants Q148H, G140S (HS) and N155H, E92Q (HQ) have reduced flexibility 
compared to the wild-type(WT) integrase in the RAL, DNA, integrase complex.  
 
Figure 7.4. Root mean square deviation (RMSD) for backbone Cα calculated (A) as a function of time 
and (B) the average RMSD over the 15 ns trajectory. 
  
 
 
7.2.2 Changes in the hydrogen bonding network alter the binding mode of 
raltegravir 
 In the WT integrase complex hydrogen bonding interactions occur between RAL and the main 
chain atoms of residues Y143 and S119 as well as with the side chains of residues T66, S119, and Q146. 
In addition, RAL makes hydrogen bonding contacts with the conserved viral DNA ends; cytosine 16 and 
adenine 17 in the IN active site (Table 7.1). In the HS mutant the interactions with S119 are maintained 
however the Y143 main chain interaction is lost and contact is only made with the Y143 side chain. 
Interestingly, the C-terminal residue R231 makes contacts with RAL and the contacts with the viral DNA 
are completely lost. 
 
Table 7.1. Hydrogen bonding interactions with raltegravir. 
  Residues involved in H-bond 
  Main chain Side chain DNA 
Wild Type Y143 
S119 
T66 
Q146 
S119 
Ade 17 
Cyt 16 
Q148H_G140S 
 
  S119 
Y143 
R231 
 
N155H_E92Q Y143 S119 Ade 17 
Cyt 16 
 
Like the WT, the HQ mutant makes main chain contacts with residue Y143, side chain of S119 
and with the viral DNA cytosine 16 and adenine 17 however the main chain S119 interaction as well as 
the side chain Q146 and T66 interactions is lost. The total number of hydrogen bonds is reduced to 36% 
of the WT in the HQ mutant and only 4% of the WT in the HS mutant. These changes in total hydrogen 
bonding interactions as well as specific contacts alter the shape of the RAL binding pocket and therefore 
change the binding mode of RAL in the mutants compared to the WT (Figure 7.5). The differences in 
  
 
hydrogen bonding contacts between the HS and HQ mutants highlight the importance of the viral DNA 
ends in RAL binding.  
 
Figure 7.5 Hydrogen bonding interactions between HIV-1 IN and RAL (A) WT Complex (B) 
Q148H_G140S Complex (C) N155H_E92Q Complex. Residues involved in hydrogen bond with RAL 
are shown in sphere representation to demonstrate their van der Waals volume. 
 
7.2.3 Changes in viral DNA interactions cause conformational changes of the 
integrase active site 
 Main chain hydrogen bonding contacts with residues D207, I141, Q146, R263, S147, S153 and 
V150 observed in the WT complex are lost in the HS complex while hydrogen bonding interactions are 
gained  with residues C65, G189, G190, G247, I208, P145, R262 and  interestingly the G140S mutation 
(Figure 7.6).   The hydrogen bonding interactions in the WT complex with residues H67, D139, I141, 
Q146, S153, V150, D207, and E246 are lost in the HQ mutant while interactions with glycine residues 
G189, G190, G192 and G247 are gained. These changes in the hydrogen bonding network between IN 
and the viral DNA correspond to a 30% increase in the HS mutant and a 12% decrease in the HQ mutant. 
These changes in non-covalent interactions result in a conformational change of the viral DNA in the IN 
active site (Figure 7.6). This therefore alters the conformation of the RAL binding pocket and thus these 
alterations may be responsible for reduced susceptibility of RAL in the HS and HQ mutants compared to 
WT.   
  
 
 
Figure 7.6 Alternative DNA binding pocket caused by RAL resistant mutations Q148H, G140S, N155H 
and E92Q. Residues involved in hydrogen bonding networks with the viral DNA are shown in sphere 
representation. Viral DNA is shown in cartoon model. 
  
 
 
7.3 Discussion 
 Treatment of HIV-1 infection with the integrase strand transfer inhibitor RAL has been shown to 
lead to the development of RAL resistant HIV-1 IN variants. The double mutations Q148H, G140S (HS) 
or N155H, E92Q (HQ) cause a 100-fold decrease in susceptibility to RAL and other integrase strand 
transfer inhibitors (Table 7.2). To understand the structural mechanisms of RAL resistance in these two 
mutation pathways, we generated a model of the full length HIV-1 integrase and performed 15 ns 
molecular dynamics simulations on the mutants as well as the WT in complex with the conserved viral 
DNA template and RAL. 
Table 7.2 Published in vitro susceptibility data of HS and HQ raltegravir resistance integrase mutants 
 Fold change compared to wild type susceptibility
¥
 
 Raltegravir Elvitegravir Dolutegravir 
148H + 140S >150 >150 3 
155H + 92Q 80-150 125-150 3 
¥ Data were combined from six references in the Stanford HIV Drug Resistance Database and compiled 
by Blanco et al., 2011 [49, 89, 194-198]. 
 
  Our results suggest that the mutations cause a reduction in protein flexibility as indicated by the 
decrease in RMSD and changes in the hydrogen bonding network between IN and RAL. In addition, 
changes in the hydrogen bonding network between IN and the viral DNA cause conformational changes 
in the active site. These differences in conformational flexibility compared to the WT therefore alter the 
binding pocket of RAL.  
 This change in the RAL binding pocket subsequently causes a change in the binding mode of 
RAL therefore pushing the metal chelating oxygen atoms out of range to interact with the Mg2+ cofactors 
in the active site. This effectively reduces the efficacy of RAL inhibition in the mutant integrase 
complexes. Understanding the mutation induced conformational changes can lead to the design of 
  
 
modified strand transfer inhibitors which help to stabilize RAL in the active site by making additional 
contacts to the mutated residues. 
7.4 Author’s contribution 
The author developed the full length HIV-1 integrase model, performed the molecular dynamics 
simulations and did the analysis of the MD trajectories.  
  
 
Chapter 8: Future Directions 
 Treatment options for the treatment of multi-drug resistant HIV-1 infection are severely limited. 
The goal of this work was to elucidate the structural mechanisms of drug resistance and furthermore to 
use that information to design modified compounds to target drug resistant variants.  
8.1. HIV-1 Protease 
 We plan to perform molecular dynamics on the top scoring lopinivir analogs, identified in 
Chapter 4, in complex with the Detroit isolates characterized in Chapter 5. We have expressed and 
purified MDR 769 with the L33F mutation common to all of the Detroit isolates. We will explore the 
structural implications on drug resistance as a result of this novel mutation with X-ray crystallography 
and molecular dynamics studies. In addition we will synthesize P1/P1’ di-fluorinated lopinavir and test 
it’s inhibitory efficacy in vitro. 
8.2. HIV-1 Integrase 
 We are planning to express and purify the full length Q148H, G140S HIV-1 integrase in complex 
with a viral DNA template and the HIV-1 integrase inhibitors raltegravir, elvitegravir and dolutegravir. In 
addition we will perform molecular dynamics, using the biologically active dimer of the full length model 
developed here, in complex with the integrase inhibitors and the viral DNA template. 
8.3. Human cancer and Charcot-Marie-Tooth Disease Type 1 B 
 Structure based drug design could aid in making synthetic decisions on not only modified 
compounds for the treatment of HIV-1 but has applications in any target system. We are currently using 
the concepts we have gained from this work in understanding the molecular pathology of Charcot-Marie –
Tooth disease Type 1B, a genetic neurological disorder and designing peptides to target mutant K-RAS, 
an important oncogene implicated in various cancers. 
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ABSTRACT 
BIOCHEMICAL, STRUCTURAL, AND DRUG DESIGN STUDIES OF MULTI-DRUG 
RESISTANT HIV-1 THERAPEUTIC TARGETS 
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Degree: Doctor of Philosophy 
Protein point mutations acquired as a mechanism of survival against therapeutics cause structural 
changes that effect protein function and inhibitor binding. This work investigates the structural 
mechanisms that lead to multi-drug resistance to HIV-1 protease and integrase inhibitors.  
Proper proteolytic processing of the HIV-1 Gag/Pol polyprotein is required for HIV infection and 
viral replication. This feature has made HIV-1 protease an attractive target for antiretroviral drug design 
for the treatment of HIV-1 infected patients, thus the development of drug resistance has arisen as a major 
therapeutic and drug design challenge. To understand the molecular mechanisms leading to drug 
resistance we selected and characterized three multi-drug resistant HIV-1 protease patient isolates, 
identifying a previously unreported structural role for V32I, I47V, I54M and L90M in protease dynamics.  
To examine the role of the P1 and P1’ positions of the substrate in inhibitory efficacy of multi-drug 
resistant HIV-1 protease 769 (MDR 769), we performed a structure-function studies. We designed a 
series of ligands and evaluated them using a combination of computational and experimental methods.  
Our results suggest two important strategies for rational drug design of protease inhibitors: (1) the 
presence of fluorinated P1 or P1’ groups enhance the binding affinities in both wild-type and MDR PR 
variants and (2) non-identical P1/P1’ residues play an important role in binding to multi-drug resistant 
HIV-1 protease.  
  
 
HIV-1 integrase is an essential enzyme necessary for the replication of the HIV virus as it 
catalyzes the insertion of the viral genome into the host chromosome. Raltegravir was the first integrase 
inhibitor approved by the FDA for treatment of HIV-1 infection. HIV patients on raltegravir containing 
regimens may develop drug resistance mutations at residue 140 and 148 in the catalytic 140’s loop 
resulting in a 5-10 fold decrease in susceptibility to raltegravir. To understand the molecular mechanisms 
of drug resistance in HIV-1 integrase we performed molecular dynamics studies on the catalytic core 
domain of raltegravir resistant HIV-1 protease in complex with raltegravir. These experiments suggest a 
gating function of the catalytic 140’s loop in active site accessibility as well as reduced flexibility as a 
mechanism of raltegravir resistance. In addition, we developed a model for the full length HIV-1 
integrase and performed molecular dynamics of our model in complex with raltegravir and the viral DNA 
ends, identifying unique alterations in non-bonded interactions between the protein, DNA, and raltegravir 
as a result of the drug resistant mutations.  
The results of this work provide detailed structural information on HIV-1 protease and integrase 
in order to aid in the development of new therapeutics against these targets. Our work has implications 
not only on HIV-1 therapy but the techniques described here can be used to study other proteins, design 
new compounds, and help aid in our understanding of protein structure.  
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